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THE PATIENT PACKAGE INSERT AND
PHARMACIST LIABILITY
I. INTRODUCTION
New patient labeling regulations promulgated by the Commis-
sioner of the Food and Drug Administration (FDA) became effective
on April 3, 1978.1 The regulations provide for revised and expanded
labeling information on oral contraceptive drug products to give the
consumer extensive "reports about the risk of blood clots, other
problems of the circulatory system, cancer, and effects on the unborn
child associated with the use of oral contraceptives." 2 The regulation
further requires that the patient package insert (PPI) be provided by
the pharmacist or other dispenser to each patient to whom the drug is
delivered. At this time, a PPI is required only for the oral contracep-
tives, for products containing estrogen,3 and for the post-coital contra-
ceptive, diethylstilbestrol.4 The Commissioner has, however, proposed
patient labeling for all prescription drugs.5 Both Houses of Congress,
in proposing comprehensive reforms of existing federal law governing
drugs administered to humans, have introduced legislation requiring
detailed labeling directed at the patient.6 The existing regulations and
the proposed legislation may have far-reaching effects on the pharma-
ceutical delivery system, not only for the pharmaceutical manufac-
turer7 and for the prescribing physician,' but also for the dispensing
pharmacist and for the consumer. This comment will explore the in-
creased potential liabilities of the pharmacist, both statutory9 and judi-
1. 21 C.F.R. § 310.501(a)(I).
2. Id For an example of the required patient insert, see App. B & C.
3. 21 C.F.R. § 310.5 15 (1978).
4. 21 C.F.R. § 310.501(b) (1978).
5. 40 Fed. Reg. 15,392 (1975).
6. S. 2755, 95th Cong., 2d Sess. (1978). The House version, H.R. 8891, 95th Cong., 1st Sess.
(1977) (cited in Gardner, Increasing Patient Awarenesr in Drug Therapy: Rami(fcations of/a Patient
Package Insert Requirement, 66 GEo. L.J. 837, 840 n.14 (1978)) provides that a drug will be
deemed mislabeled if not dispensed with a patient package insert. Id § 5(a). See notes 28-38
infra and accompanying text.
7. For a recent analysis of the impact of the PPI on the manufacturer see Gardner, supora
note 6, at 855-60. This comment will expand Gardner's article to include the additional ramifica-
tions that the PPI may present to the dispensing pharmacist.
8. Id at 860-67.
9. See notes 29-38 infra and accompanying text.
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cially imposed, l° when delivery of a PPI to the patient is omitted. It
will be shown that these liabilities can arise from the breach of a duty
to warn the patient-using theories of negligence 1 and of strict liabil-
ity 2 -as well as from the breach of a warranty. 13
II. FEDERAL STATUTORY LIABILITY
When the Commissioner of the FDA first proposed PPI require-
ments,' 4 many comments were received expressing doubt that the
Commissioner had the authority to promulgate those regulations.'
The comments argued that
the enactment of Section 503(b)(2) [of the Federal Food,
Drug and Cosmetic Act (FDCA)] 6 . . in 1951, reflected a
10. See notes 40-88 infra and accompanying text.
11. See notes 54-88 infra and accompanying text.
12. See notes 60-88 infra and accompanying text.
13. See notes 89-129 infra and accompanying text.
14. 40 Fed. Reg. 15,392 (1975).
15. 43 Fed. Reg. 4,214 (1978). This comment does not attempt a complete statutory analysis
of the FDA's rule-making authority. Only a brief synopsis of the issue is presented here. For a
detailed discussion of the Commissioner's legal authority to promulgate PPI regulations, see
Gardner, supra note 6, at 839, and McNamara, The New Age ofFD,4 Rule-Making, 31 FOOD-
DRUG-COSM. L.J. 393 (1976). For a complete presentation of the administrative comment proce-
dure employed by the FDA, see generally Jurow, A Look at FD.4 s History and Future, 28 FOOD-
DRUG-CosM. L.J. 518 (1973); Marcus, The New FDA Hearing Regulations-An Analysis, 29
FoOD-DRUG-CosM. L.J. 336 (1974); Peskoe, Submissions and Petitions Under the FDA "s Procedu-
ral Regulations, 32 FOOD-DRUG-CosM. L.J. 216 (1977); Willig, The Influence ofthe Federal Food,
Drug and Cosmetic Act on the Pharmacists' Current Good Dispensing Practices, 28 FOOD-DRuG-
CosNi. LJ. 636 (1973). "FDA's rule-making has been substantially the result of court litigation. It
is not, as one would assume, rule-making followed by court challenges." Epstein, New Directions
for Administrative Regulations, 30 FooD-DRUG-CosM. L.J. 384, 384-85 (1975). See also Shapiro,
The Judicial Review of RuleMaking, 28 FOOD-DRUG-CosM. L.J. 756 (1973). For an excellent
forum on FDA rule making, see Austern, Philosophy ofRegulation.'A Reply to Mr. Hutt, 28 FOOD-
DRUG-CosM. L.J. 189 (1973); Hagan, Remarks on the Regulatory Philosophy of the FDA, 28
FooD-DRUG-CosM. L.J. 195 (1973); Hutt, The Philosophy ofRegulation Under the Federal Food,
Drug and Cosmetic Act, 28 FOOD-DRUG-COsM. L.J. 177 (1973); Kennedy, The New Vogue in
Rulemaking at FDA:,4 Foreward, 28 FOOD-DRuG-CosM. L.J. 172 (1973); Montgomery, Comments
on the Philosoph, ofRegulation Under the Federal Food, Drug and Cosmetic Act, 28 FOOD-DRuo-
Cosm. L.J. 201 (1973). Peter Hutt, past Assistant General Counsel for the FDA, developed the
Federal Register notice system with commentary for each proposed regulation. Epstein, New Di-
rectionsfor Administrative Regulations, 30 FOOD-DRUG-CosM. L.J. 384, 394 (1973). The system,
although lauded by some, has critics within the food and drug bar. See Merrill, Administrative
Rule Making, 30 FOOD-DRUG-CosM. L.J. 478, 479-81 (1975). But see Austern, The Regulatory
Gospel,4ccording to Saint Peter, 29 FOOD-DRUG-CosM. L.J. 316 (1974).
16. 21 U.S.C. § 353(b)(2) (1970). Section 353(b)(2) provides:
(2) Any drug dispensed by filling or refilling a written or oral prescription of a
practitioner licensed by law to administer such drug shall be exempt from the require-
ments of section 352 of this title, except subsections (a), (i) (2) and (3), (k), and (1) of said
section, and the packaging requirements of subsections (g), (h), and (p) of said section, if
the drug bears a label containing the name and address of the dispenser, the serial
number and date of the prescription or of its filling, the name of the prescriber, and, if
2
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clear understanding by Congress that prescription drugs need
not bear labeling containing directions for patient use and
that this section exempts prescription drugs at the time the
drug is dispensed by the pharmacist from any requirement
that the labeling bear adequate directions for use and warn-
ings under Section 502(f) of the Act.'7
The Commissioner responded to this comment by pointing out
that "[t]he primary purpose of the provision in section 503(b)(2) of the
Act exempting a prescription drug from adequate directions for use
and warnings is to avoid self-diagnosis and self-administration of drugs
that require professional supervision for safe use."18 The Commis-
sioner contends that a PPI will not encourage self-diagnosis or adminis-
tration but, instead, "will inform the patient of the advantages and risks
associated with the use of these drugs and insure safe and effective use
. . . after it has been prescribed by the physician."' 19
At any rate, it is arguable that the self-medication problem will
exist to the same extent even after a PPI delivery requirement is insti-
tuted. Patients may frequently save the last of a prescription for use the
next time the same symptoms occur. The patient is thus self-diagnos-
ing and self-medicating. Since a PPI would detail the indications for
the drug's use,20 it is conceivable that a PPI would increase the inci-
dence of self-medication, rather that limit it as the Commissioner con-
tends.21
Although the self-medication argument appears inconclusive, an-
stated in the prescription, the name of the patient, and the directions for use and caution-
ary statements, if any, contained in such prescription. This exemption shall not apply to
any drug dispensed in the course of the conduct of a business of dispensing drugs pursu-
ant to diagnosis by mail, or to a drug dispensed in violation of paragraph (1) of this
subsection.
17. 42 Fed. Reg. 37,656 (1977).
18. Id
19. See also Guarino, Patient Package Inserts, 34 FOOD-DRuG-CosM. L.J. 116 (1979).
20. See App. A.
21. 42 Fed. Reg. 37,636 (1977). This semantic distinction tends to break down when consid-
ering a refillable prescription drug. When first dispensed to the patient, a PPI would seem to
function as the Commissioner contends, as a concise statement of the effects of the drug and the
purpose for which the physician has prescribed it. Any unused portion of the original prescription
or an authorized refill, however, may be used contrary to the use envisioned by the Commis-
sioner's rationale for the PPI. For example, when seemingly similar symptoms appear, the patient
may consult his PPI from the original prescription, conclude that the etiology is therefore similar,
and begin to self-medicate with a potentially dangerous pharmaceutical. Even worse, perhaps, is
the situation where the patient transfers the unused portion to a third person who exhibits similar
symptoms. The knowledge the patient acquires concerning the advantages and risks of his pre-
scription is heavily outweighed by the possibility of self-medication, thereby defeating any merito-
rious purpose of a PPI.
[Vol. 14:590
3
Walker: The Patient Package Insert and Pharmacist Liability
Published by TU Law Digital Commons, 1978
1979] PHARMA CIST LIABILITY
other position taken by the Commissioner is more substantial and, with
the reinforcement of case law, does justify FDA rule-making authority
regarding drug labeling. It was argued in comments to the proposed
regulations on estrogenic drug products labeling22 that section 701 (a)23
of the FDCA authorizes only the promulgation of substantive regula-
tions on subjects specifically authorized by the Act. In National Nutri-
tional Foods Association v. Weinberger,24 the court recognized that "if
the administrative process is to be practically effective, specific regula-
tions promulgated pursuant to a general statutory delegation of author-
ity must be treated as authoritative, whether labeled 'substantive' or
'interpretive,' especially in areas where the agency possesses expertise
not shared by the courts."25 Based on this, the Commissioner con-
cluded that section 701(a) empowers him to issue substantive rules to
facilitate enforcement of the Act; therefore, a regulation issued pursu-
ant to section 701(a) "may lawfully establish a requirement for patient
labeling for a prescription drug product."26
Assuming that the Commissioner does possess the authority to
promulgate labeling rules and that the rules do have the force and ef-
fect of statutory law, the impact on the dispensing pharmacist must
next be considered. 7 Statutory liability for misbranding of a drug
product is controlled by section 502 of the FDCA.28  A dispensing
22. 42 Fed. Reg. 37,636 (1977).
23. 21 U.S.C. § 371(a) (1976).
24. 512 F.2d 688 (2d Cir.), cert. denied, 423 U.S. 827 (1975) (injunctive relief sought by man-
ufacturers against regulations classifying high level vitamins as prescription drugs).
25. 512 F.2d at 696.
26. 42 Fed. Reg. 37,636 (1977). See also Weinberger v. Hynson, Westcott, & Dunning, Inc.,
412 US. 609 (1973); Ciba Corp. v. Weinberger, 412 U.S. 640 (1973); and USV Pharmaceutical
Corp. v. Weinberger, 412 U.S. 655 (1973), decided the same day and upholding the validity of
FDA administrative summary judgment procedures as applied to withdrawal of new drug appli-
cations.
27. Although the regulation as finally written requires that the dispenser distribute the PPI,
this article will be limited to the dispensing pharmacist. The Commissioner has stated that the
PPI regulation, 21 C.F.R. § 310.501(a)(1) (1978), for oral contraceptives applies to "physicians,
nurses, lay persons or semi-professionals in a family planning clinic or student health department,
as well as a pharmacist." 43 Fed. Reg. 4,214-215 (1978). The textual material will apply to each if
he is functioning in a dispensing capacity.
28. 21 U.S.C. § 352 (1976). Section 352 reads:
A drug or device shall be deemed to be misbranded-
(a) If its labeling is false or misleading in any particular.
(b) If in package form unless it bears a label containing (1) the name and place of
business of the manufacturer, packer, or distributor; and (2) an accurate statement of the
quantity of the contents in terms of weight, measure, or numerical count: Provided, That
under clause (2) of this subsection reasonable variations shall be permitted, and exemp-
tions as to small packages shall be established, by regulations prescribed by the Secre-
tary. (c) If any word, statement, or other information required by or under authority of
4
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pharmacist would be in violation of section 502(p) if he dispenses a
this chapter to appear on the label or labeling is not prominently placed thereon with
such conspicuousness (as compared with other words, statements, designs, or devices, in
the labeling) and in such terms as to render it likely to be read and understood by the
ordinary individual under customary conditions of purchase and use.
(d) If it is for use by man and contains any quantity of the narcotic or hypnotic
substance alpha eucaine, barbituric acid, betaeucaine, bromal, cannabis, carbromal,
chloral, coca, cocaine, codeine, heroin, marihuana, morphine, opium, paraldehyde, pe-
yote, or sulphonmethane; or any chemical derivative of such substance, which derivative
has been by the Secretary, after investigation, found to be, and by regulations designated
as, habit forming; unless its label bears the name and quantity or proportion of such
substance or derivative and in juxtaposition therewith the statement "Warning-May be
habit forming."
(f) Unless its labeling bears (1) adequate directions for use; and (2) such adequate
warnings against use in those pathological conditions or by children where its use may
be dangerous to health, or against unsafe dosage or methods or duration of administra-
tion or application, in such manner and form, as are necessary for the protection of users:
Provided, That where any requirement of clause (1) of this subsection, as applied to any
drug or device, is not necessary for the protection of the public health, the Secretary shall
promulgate regulations exempting such drug or device from such requirement.
(g) If it purports to be a drug the name of which is recognized in an official com-
pendium, unless it is packaged and labeled as prescribed therein: Provided, That the
method of packing may be modified with the consent of the Secretary. Whenever a drug
is recognized in both the United States Pharmacopoeia and the Homoeopathic
Pharmacopoeia of the United States, it shall be subject to the requirements of the United
States Pharmacopoeia with respect to packaging and labeling unless it is labeled and
offered for sale as a homoeopathic drug, in which case it shall be subject to the provisions
of the Homoeopathic Pharmacopoeia of the United States, and not to those of the
United States Pharmacopoeia: Providedfurther, That, in the event of inconsistency be-
tween the requirements of this subsection and those of subsection (e) of this section as to
the name by which the drug or its ingredients shall be designated, the requirements of
subsection (e) of this section shall prevail.
(h) If it has been found by the Secretary to be a drug liable to deterioration, unless
it is packaged in such form and manner, and its label bears a statement of such precau-
tions, as the Secretary shall by regulations require as necessary for the protection of the
public health. No such regulation shall be established for any drug recognized in an
official compendium until the Secretary shall have informed the appropriate body
charged with the revision of such compendium of the need for such packaging or label-
ing requirements and such body shall have failed within a reasonable time to prescribe
such requirements.
(i) (I) If it is a drug and its container is made, formed, or filled as to be misleading;
or (2) if it is an imitation of another drug; or (3) if it is offered for sale under the name of
another drug.
(j) If it is dangerous to health when used in the dosage or manner, or with the
frequency or duration prescribed, recommended, or suggested in the labeling thereof.
(k) If it is, or purports to be, or is represented as a drug composed wholly or partly
of insulin, unless (I) it is from a batch with respect to which a certificate or release has
been issued pursuant to section 356 of this title, and (2) such certificate or release is in
effect with respect to such drug.
(1) If it is, or purports to be, or is represented as a drug (except a drug for use in
animals other than man) composed wholly or partly of any kind of penicillin, streptomy-
cin, chlortetracycline, chloramphenicol, bacitracin, or any other antibiotic dru , or any
derivative thereof, unless (1) it is from a batch with respect to which a certificate or
release has been issued pursuant to section 357 of this title, and (2) such certificate or
release is in effect with respect to such drug: Provided, That this subsection shall not
apply to any drug or class of drugs exempted by regulations promulgated under section
357(c) or (d) of this title.
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pharmaceutical product that is labeled contrary to FDA regulation.29
The applicable FDA regulation3" requires the manufacturer (in this
case, of the oral contraceptive) to supply the pharmacist with the cur-
rent PPI for that product3 ' and for the pharmacist to then deliver the
PPI to the patient.32 Failure to do so would constitute violation of the
regulation and therefore a violation of section 502(p). The omission
would be a federal offense, punishable by up to one year imprisonment
or a fine of not more than $1,000.00, or both.33
A serious question of liability to the consumer is raised by viola-
tion of a misbranding statute. If section 502 is determined to be a
safety statute,34 its violation through misbranding could constitute neg-
(n) In the case of any prescription drug distributed or offered for sale in any State,
unless the manufacturer, packer, or distributor thereof includes in all advertisements and
other descriptive printed matter issued or caused to be issued by the manufacturer, pack-
er, or distributor with respect to that drug a true statement of(l) the established name as
defined in subsection (e) of this section, printed prominently and in type at least half as
large as that used for any trade or brand name thereof, (2) the formula showing quantita-
tively each ingredient of such drug to the extent required for labels under subsection (e)
of this section, and (3) such other information in brief summary relating to side effects,
contraindications, and effectiveness as shall be required in regulations which shall be
issued by the Secretary in accordance with the procedure specified in sections 371(e) of
this title: Provided, That (A) except in extraordinary circumstances, no regulation issued
under this subsection shall require prior approval by the Secretary of the content of any
advertisement, and (B) no advertisement of a prescription drug, published after the effec-
tive date of regulations issued under this subsection applicable to advertisements of pre-
scription drugs, shall, with respect to the matters specified in this subsection or covered
by such regulations, be subject to the provisions of sections 52 to 57 of Title 15. This
subsection (n) shall not be applicable to any printed matter which the Secretary deter-
mines to be labeling as defined in section 32 1(m) of this title.
(p) If it is a drug and its packaging or labeling is in violation of an applicable
regulation issued pursuant to section 1472 or 1473 of Title 15.
29. 21 U.S.C. § 352(p) (1976).
30. 21 C.F.R. § 310.501(a)(1) (1978).
31. The FDA intends to publish updated versions of the PPI in the Federal Register as
changes occur. The manufacturer is thus effectively put on notice that changes may occur and
failure to revise will result in misbranding by the manufacturer. Id. § 310.501(a)(8).
32. This delivery requirement presents practical and economic disadvantages to the use of
PPIs. For the manufacturer, the cost of development and distribution of the PPI will inevitably be
reflected in the prescription cost. Also, and perhaps more significantly, the requirement of the PPI
may prolong the approval of the new drug application process, a procedure that already takes
many years and millions of dollars. See generally Goldstein, On the Road with American Drug
Corpanies, 12 TRIAL 43 (1976), and Parker, Regulating Pharmaceutical Innovation: An Econo-
mist's View, 32 FOOD-DRUG-COsm. L.J. 160, 172-74 (1977).
The pharmacist will have to develop an efficient distribution system to insure that each pa-
tient receives the required labeling, with resulting cost increases in prescription pricing. Seegener-
ally Weigel, New Regulatory Concepts in Rx Labelingfor Patients, 31 FOOD-DRUG-CosM. L.J. 531
(1976). From a legal point of view, the pharmacist should also develop a system to prove that the
patient received the PPI, perhaps by requiring a signature from the patient at the time of prescrip-
tion delivery to serve as proof that a PPI was delivered.
33. 21 U.S.C. § 333(a) (1976).
34. "Violation of a pure food and drug act has been held sufficient to show negligence and
6
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ligence per se. 11 "The effect of such a rule is to stamp the [defendant
pharmacist's] conduct as negligence, with all the effects of common law
negligence."36 If a court should find that the FDCA was "so clearly
intended to protect a particular class of persons against their own in-
ability to protect themselves . . . the policy of the legislature is inter-
preted to mean that [ordinary negligence defenses of contributory
negligence and assumption of the risk] are not available [to a defend-
ant]."37 Thus, it can be seen that failure to deliver a PPI to a patient,
clearly a misbranding violation under section 502, can potentially give
rise to tort liability which would not exist in the absence of such a stat-
ute.38
permit a recovery since these statutes are enacted for the public's protection from the very harm
suffered." Cotton, .4 Note on the CivilRemedies ofLnjured Consumers, I L. & CONTEMP. PROD. 67,
72, n.37 (1933) (citing Armour v. Wanamaker, 202 F. 423 (3d Cir. 1913), and Meshbesher v.
Channellene Oil & Mfg. Co., 107 Minn. 104, 119 N.W. 428 (1909)). See also United States v.
Various Quantities of Articles of Drug, 83 F. Supp. 882 (D.D.C. 1949).
35. W. PROSSER, HANDBOOK OF THE LAW OF TORTS § 36, at 200 (4th ed. 1971).
Once a statute is determined to be applicable-which is to say, once it is interpreted
as designed to protect the class of persons in which the plaintiff is included, against the
risk of the type of harm which has in fact occurred as a result of the violation-the great
majority of the courts hold that an unexcused violation is conclusive on the issue of
negligence.
Id The classic case interpreting when a plaintiff is included in the "class of persons to be pro-
tected" is Gorris v. Scott, [18741 9 Ex. D. 125, holding that a statute requiring footholds and pens
on a cattleship to prevent disease would not operate to create liability when the defendant failed to
so equip his ship and cattle were subsequently washed overboard in a storm. For a general discus-
sion on the issue of negligence per se, see Kennelly, Safety Statutes and Ordinances-Their Appli-
cation and Construction, 19 TRIAL LAW GUIDE 323 (1975); Lowndes, Civil Liability Created by
Criminal Legislation, 16 MINN. L. REv. 361 (1932); Comment, Negligence-Violation of Safety
Regulations as Negligence Per Se: The Perishable Sanction, 62 Ky. L.J. 254 (1973). It seems clear
that violation of the FDCA will result in personal criminal liability, as was held in United States v.
Dotterweich, 320 U.S. 277 (1943) (imposing vicarious criminal liability on the president of a drug
company for shipping misbranded and adulterated drugs in interstate commerce). The question
of whether a court should imply a private cause of action for violation of a federal regulator;,
statute has been debated for many years. "If a plaintiff can prove to a court that the defendant's
violation of the Act [the FDCA] proximately caused him physical or economic harm, a court
should imply a remedy on his behalf . . .[Tihere is nothing in the Act or its history to prevent a
court from doing this." Cole & Shapiro, Private Litigation Under the Federal Food, Drug and
Cosmetic Act: Should the Right to Sue Be Implied?, 30 FOOD-DRUG-CoSM. L.J. 576, 610 (1975).
Contra, Sales, Does the Food, Drug and Cosmetic Act Create a Private Right of Action?, 28 FOOD-
DRUG-CosM. L.J. 501, 511 (1973) ("The inescapable conclusion is that the [FDCA] does not pro-
vide a private right of action nor may one be implied. Congress expressly rejected all proposals
that might have justified such an action."). See generally O'Neill, Public Regulation and Private
Rights ofAction, 52 CALIF. L. REV. 231 (1964); Words, The Effect of the Food, Drug, and Costnetic
Act on Private Litigation, 18 FOOD-DRUG-CosM. L.J. 511 (1963); Note, Implying Civil Remedies
from Federal Regulatory Statutes, 77 HARV. L. REv. 285 (1963).
36. W. PROSSER, supra note 35, § 36, at 200
37. Id. at 201. See also Morris, The Role of Administrative Safety Measures in Negligence
Actions, 28 TEx. L. REv. 143 (1949).
38. See discussion of informed consent at notes 78-82 infra and accompanying text.
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III. TORT LIABILITY
A. Negligence and Strict Liability-The Duty to Warn
To recover under the tort theory of negligence, a plaintiff must
show (1) a duty, (2) a breach of that duty, (3) causation or proximate
cause, and (4) actual damage or loss resulting from the breach.39 The
historical standard of care owed to the patient by the pharmacist re-
quires "such precautions as are liable to prevent death or serious injury
to those who may, in the ordinary course of events, be exposed to the
dangers incident to traffic in which he is engaged .. ". . ,o The con-
cept may also be stated in the classical tort language of professional
duty: "[The pharmacist is] required to have that reasonable degree of
learning and skill which is ordinarily possessed by other druggists in
good standing as to qualifications in similar communities."'" The
pharmacist's duty of care encompasses a duty to warn the patient of
dangers connected with the drugs and medicines he compounds and
sells.42 This duty, combined with the special knowledge of the drugs he
dispenses,43 creates unique liabilities for the pharmacist. It has been
held that a pharmacist who sells a drug which is "harmless in itself, but
is to be mixed with, or used in connection with, another which would
then have an injurious effect, of which the purchaser has no knowledge,
should advise the purchaser of it, and a failure to do so would make
him liable for the consequences."'  Gibson v. Torbert,45 decided in
39. W. PROSSER, supra note 35, § 30. For purposes of this comment, it will be presumed that
these four elements are present. Therefore, it must also be presumed that, not only did the phar-
macist breach his statutory duty to deliver a PPI, but also that the patient was harmed by adminis-
tration of the drug. The incidence of these two conditions occuring remains to be seen. The
remainder of this comment explores possible causes of action a patient/plaintiff might have
against the dispensing pharmacist if these two conditions are met.
40. Corona Coal Co. v. Sexton, 21 Ala. App. 52,-, 105 So. 716, 717 (1925). See also John-
son v. Primm, 74 N.M. 597, 396 P.2d 426 (1964) (pharmacist might be liable for plaintiffs addic-
tion caused by providing drug in excess of prescribed dosage if there was a showing that
pharmacist knew of habit-forming nature of drug).
41. Tremblay v. Kimball, 107 Me. 53, -, 77 A. 405, 407 (1910).
42. "One dealing in dangerous drugs owes to the public a positive and active duty to limit the
danger by labeling or otherwise conveying knowledge thereof." Miller v. New Zealand Ins. Co.,
98 So. 2d 544, 546 (La. 1957). Cf. Love v. Wolf, 226 Cal. App. 2d 378, 38 Cal. Rptr. 183 (1964)
(overpromotion may counteract warning given).
43. "A druggist is undoubtedly held to a special degree of responsibility... corresponding
with his superior knowledge of the business." Marigny v. Dejoie, 172 So. 808, 810 (La. 1937)
(citing Thomas v. Winchester, 6 N.Y. 397 (1852) (pharmacist delivered poisonous pills by mis-
take)).
44. Krueger v. Knutson, 261 Minn. 144, -, 111 N.W.2d 526, 532 (1961).
45. 115 Iowa 163, 88 N.W. 443 (1901).
8
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Iowa at the turn of the century, however, severely limited the pharma-
cist's duty to warn by stating that
[i]t has been said that when a person who has reached the age
of discretion, and who is apparently in possession of his
mental faculties, applies to the druggist for a certain drug, he
represents to the dealer, by implication, at least, that he knows
its properties and uses, and that he is a fit person to whom sale
thereof may be made, and that unless there is something...
to indicate that the would-be purchaser cannot be entrusted
with the substance, a sale. . . , may be made without explain-
ing its properties or the manner in which it may be safely used
or handled and . . . the seller is not liable in damages for
injuries . . . , no matter how little knowledge the purchaser
may in fact have had of its properties, or of the manner in
which it could safely be handled.46
Although Gibson has never been expressly overruled or judicially lim-
ited, it is doubtful that a court today would go to such extremes in light
of prevalent consumer protection attitudes. The Gibson decision has
several interesting analogies to the PPI. First, again using the Commis-
sioner's reasons for instituting PPI delivery, the purpose of the PPI is to
better enable the patient to participate in the prescription drug regimen
delivery system.47 If the patient is supplied with an accurate, up-to-
date PPI (applying the Gibson holding), the liability of the dispensing
pharmacist is actually decreased because he may assume, within the
limitations of the information actually contained in the PPI, that the
patient knows the drug's properties and the manner in which the drug
may safely be used.
In California, it has been held that failure to follow instructions
given by a physician constitutes a complete defense of contributory
negligence in a medical malpractice case.4" It is possible that, if the PPI
46. Id at 164, 88 N.W. at 445.
47. 43 Fed. Reg. 4,214-215 (1978). The prescription system as it now operates for all nones-
trogen pharmaceuticals includes primarily the physician diagnosing and prescribing the drug and
the pharmacist, following the physician's orders, then dispensing the prescription. The patient,
though the beneficiary of this delivery system, has little input about what is dispensed to him.
Apparently, the Commissioner intends, by requiring PPIs, to give the patient a greater role in the
delivery system, at least to the extent that the patient has the information at hand to participate in
the decision to assent to a prescription drug regimen.
48. Preston v. Hubbell, 87 Cal. App. 2d 53, 196 P.2d 113 (1948) (plaintiff was contributorily
negligent in failing to follow post-operative care instructions). See also Maertins v. Kaiser Found.
Hosp., 162 Cal. App. 2d 661, 328 P.2d 494 (1958) (plaintiff ignored instructions to return for
treatment). See Kouri, The Patients Duty to Cooperate, 3 REvuE DE DROIT UNIVERSITIE DE SHER-
BROOKE 43 (1972).
[Vol. 14:590
9
Walker: The Patient Package Insert and Pharmacist Liability
Published by TU Law Digital Commons, 1978
PHARM4 CIST LIABILITY
is delivered and the instructions and warnings are not followed, a de-
fense of contributory negligence may be raised effectii ely by the phar-
macist if injury results.49
If the patient received the PPI and was harmed as a result of the
prescription, assumption of risk should also operate to cut off the phar-
macist's liability. The patient is presumed to know the possible adverse
effects of the drug which are listed in the PPI and, by continuing ther-
apy, gives free and informed consent to that drug treatment:50 Thus, it
can be seen that, f the PPI is delivered, the liability of the pharmacist
may actually be decreased because the pharmacist's duty to warn is
fulfilled. Conversely, failure to deliver a PPI would leave the patient
without information about the drug prescribed for him. It is probable
that the courts would presume the pharmacist to have been aware of
the fact that the patient was uninformed about the properties of the
drug and therefore hold him liable for any adverse effects caused by his
omission.-"
Without the delivery of a PPI, assumption of risk as a defense may
be raised only upon a showing that the patient voluntarily took the
drug after learning, by means other than the PPI, all information that
the PPI would have disclosed.5" Such a showing would be difficult at
best. Gibson notwithstanding, it would be a rare patient who would
have the requisite specialized knowledge of a drug's hazards, and it
would be unrealistic to assume as much.
As will be shown, the pharmacist today should have an affirmative
duty to warn,53 and breach of that duty will subject him to liability, the
extent of which the remainder of this section will examine. Tradition-
ally, the concept of a duty to warn as applied to prescription
pharmaceuticals sounded in negligence and suit was brought primarily
against the manufacturer.54 The manufacturer's duty to warn has been
49. See generaly W. PROSSER, supra note 35, § 65; Note, Contributory Negligence as a De-
fense to Medical Malpractice in California, 8 U.S.F.L. REv. 386 (1973).
50. See generally Keeton, Assumption of Risk in Products Liability Cases, 22 LA. L. REv. 122
(1961). Informed consent is discussed at notes 78-82 infra and accompanying text.
51. See notes 60-88 infra and accompanying text.
52. W. PROSSER, supra note 35, § 68, at 440. See also Keeton, supra note 50, at 145-46.
53. Krueger v. Knutson, 261 Minn. 144, 111 N.W.2d 526 (1961). See RESTATEMENT (SEc-
OND) OF TORTS § 402A, comment k, at 353 (1965), and notes 67-88 infra and accompanying text.
54. Salmon v. Parke, Davis & Co., 520 F.2d 1359 (4th Cir. 1975) (manufacturer must exercise
reasonable care commensurate with the risk, to warn physicians); Schenebeck v. Sterling Drug,
Inc., 423 F.2d 919 (8th Cir. 1970) (manufacturer has continuous duty to warn physicians of dan-
gers of drug); Sterling Drug, Inc. v. Cornish, 370 F.2d 82 (8th Cir. 1966) (duty to warn doctors
even though only a small number of people would experience the particular side effect).
19791
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held repeatedly to be a duty to warn only the prescribing physician, not
the ultimate consumer, the patient. 5  This duty was fulfilled mainly
through the use of the package insert56 included with each pharmaceu-
tical packaged by the manufacturer (though given to the pharmacist
and usually not to the physician) and compiled in the Physicians' Desk
Reference. The manufacturer's duty to warn is also met through drug
advertising which is required to detail all the drug's uses, contraindica-
tions, and adverse effects, and through the promotional efforts of the
"detail man," the manufacturer's representative who personally con-
tacts the physician to promote the manufacturer's drug products.5 7 Li-
ability has been based on the assumption that the manufacturer is "in
the best position to prevent injuries resulting from the use of prescrip-
tion drugs. '58  The prescribing physician, on the other hand, if effec-
55. See, e.g., Salmon v. Parke, Davis & Co., 520 F.2d 1359 (4th Cir. 1975); Schenebeck v.
Sterling Drug, Inc., 423 F.2d 919 (8th Cir. 1970). But see Cunningham v. Charles Pfizer & Co.,
532 P.2d 1377 (Okla. 1974) (manufacturer's duty to warn extends to ultimate consumer-the polio
vaccine recipient).
The FDCA has been used by the courts to impose negligence upon a manufacturer based
upon a failure to adhere to the Act's requirements. See Toole v. Richardson-Merrell, Inc., 251
Cal. App. 2d 689, 60 Cal. Rptr. 398 (1967) (violation of new drug reporting provision, codified in
21 C.F.R. § 330.10 (1978), gave rise to a presumption of negligence); McEwen v. Ortho Pharma-
ceutical Corp., 270 Or. 375, 528 P.2d 522 (1974) (liability imposed for injuries caused by inade-
quate FDA approved labeling, ie, the physician package insert). The McEiven court went on to
hold that FDCA requirements "may be only minimal in nature when the manufacturer or sup-
plier knows of, or has reasons to know of, greater dangers not included in the warning, its duty to
warn may not be fulfilled .... " id at -, 528 P.2d at 534 (citing Stevens v. Parke, Davis & Co., 9
Cal. 3d 51, 507 P.2d 643, 107 Cal. Rptr. 45 (1973)), and that the warnings given by an ethical drug
manufacturer may be found inadequate, "[a]lthough all the government's regulations and require-
ments have been satisfactorily met in the production and marketing of the pharmaceutical and in
the changes made in the literature." Id at 534 (citing Yarrow v. Sterling Drug, Inc., 263 F. Supp.
159, a_'d, 408 F.2d 978 (8th Cir. 1969)). See Henteleff, The Interrelationships OfFDA Laws and
Regulations with Product Liabilit y Issues, 32 Bus. LAW. 1029 (1977).
56. See App. C.
57. One consistent theme of the Parke, Davis/Chloromycetin cases is the effect of manufac-
turer overpromotion on physician liability. Though the package insert gave adequate warnings,
the "detail" men of the manufacturer (ie., the manufacturer's sales representatives) negated the
warnings by minimizing the risks in their presentations to the physicians, resulting in over-pre-
scribing of Chloromycetin in situations where the antibiotic was of little or no use or even contra-
indicated, with attendant fatalities caused by drug-induced blood dyscrasias. See, e.g., Stevens v.
Parke, Davis & Co., 9 Cal. 3d 51, 67, 507 P.2d 653, 662, 107 Cal. Rptr. 45, 54 (1973); Incollingo v.
Ewing, 444 Pa. 263, 289, 282 A.2d 206, 220 (1971). See generally Note, Torts-Products Liabil-
ity-Manufacturer Held Negligently Liablefor Failure to Warn of Ethical Drug's Dangers By "Wa-
tering Down" Its Warning and Overpromoting Its Drug, 23 CATH. U.L. REV. 189 (1973); Note,
Products Liabiliy-Drug Manufacturer Liablefor Overpromotion 0/the Use 0/a Prescription Drug,
10 GA. S.B.J. 450 (1974); Comment, The Ubiquitous Detailman: An Inquiry Into His Function and
Activities and the Laws Relating to Them, I HOFSTRA L. REV. 183 (1973); Note, Torts-Products
Liability-FDA Required Warning Nullified by Manufacturer Overpromotion ofDrug, 43 U. CINN.
L. REV. 224 (1974).
58. Gardner, supra note 6, at 855. See Leibowitz v. Ortho Pharmaceutical Corp., 224 Pa.
Super. Ct. 418, 307 A.2d 449 (1973), discussing the standard placed on the manufacturer to re-
11
Walker: The Patient Package Insert and Pharmacist Liability
Published by TU Law Digital Commons, 1978
1979] PHA MACIST LIABILITY
tively warned by the manufacturer about the use and effects of the
drug, has been held liable for negligent malpractice if he either disre-
garded or was unfamiliar with the available information.5 9
The concept of the duty to warn has now evolved from use in neg-
ligence to use in strict liability as embodied in section 402A of the Re-
statement (Second) of Torts.6" Drug manufacturers who had failed to
provide adequate warnings about their products to the prescribing phy-
sician have been held strictly liable for adverse effects suffered by a
patient as a result of taking the drug.6" Strict liability and prescription
drugs seem made for each other. Comment j to section 402A62 makes
search effects of the drug and the resulting inadequacy of the package insert warnings if such
research is not continually performed, with liability accordingly imposed.
59. McCue v. Norwich Pharmacal Co., 453 F.2d 1033 (1st Cir. 1972) (manufacturer liability
cut off by physician's negligently prescribing a drug in spite of adequate warning by manufac-
turer). See also Carleton, Physician Liabilityfor Adverse Drug Reactions, 24 MED. TRIAL TECH. Q.
184 (1978). The package insert directed to the physician has frequently been held to be the stan-
dard of care in prescription writing. One case resulting from the Chloromycetin litigation held
that a deviation from the package insert labeling directions is prima facie evidence of negligence.
Mulder v. Parke, Davis & Co., 288 Minn. 332, 339, 181 N.W.2d 882, 887 (1970). See generally
Comment, Package Insertsfor Rx Drugs as Evidence in Medical Malpractice Suits, 44 U. CHI. L.J.
398 (1977). The introduction of physician package inserts as evidence in medical malpractice
trials has been excluded as hearsay when used to prove the truth of the statements they contain.
See, e.g., Allen v. Leonard, 270 Cal. App. 2d 209, 75 Cal. Rptr. 840 (1969) (dictum).
60. RESTATEMENT (SECOND) OF TORTS § 402A, at 347 (1965). Section 402A provides:
(1) One who sells any product in a defective condition unreasonably dangerous to the
user or consumer or to his property is subject to liability for physical harm thereby
caused to the ultimate user or consumer, or to his property, if:
(a) the seller is engaged in the business of selling such a product, and
(b) it is expected to and does reach the user or consumer, without substantial
change in the condition in which it is sold.
(2) The rule stated in Subsection (1) applies although
(a) the seller has exercised all possible care in the preparation of his product, and
(b) the user or consumer has not bought the product from or entered into any
contractual relation with the seller.
Id
61. Hoffman v. Sterling Drug, Inc. 485 F.2d 132 (3d Cir. 1973) (breach of duty to warn would
result in liability to user under both negligence and strict liability theories); Sterling Drug, Inc., v.
Yarrow, 408 F.2d 978 (8th Cir 1969) (if drug is manufactured without negligence, but is unreason-
ably dangerous if warning is not given, manufacturer may be held liable); Basko v. Sterling Drug,
Inc., 416 F.2d 417 (2d Cir. 1969) (manufacturer must have actual or constructive knowledge of the
hazards before the duty to warn attaches); Sindell v. Abbott Laboratories, 149 Cal. Rptr. 138
(1978) (drug manufacturers are not entitled to more lenient treatment than other manufacturers in
the area of products liability). The Basko court noted that comment k to § 402A of the Restate-
ment (Second) o/Torts adopts the ordinary negligence duty to warn standard. 416 F.2d at 426.
For further discussion of manufacturer liability, see Gardner, supra note 6, at 855.
62. RESTATEMENT (SECOND) OF TORTS § 402A, comment j, at 353 (1965). Comment j pro-
vides:
Where. . . the product contains an ingredient to which a substantial number of the
population are allergic . . . the seller is required to give warning against it, if he has
knowledge, or by the application of reasonable, developed human skill and foresight
should have knowledge, of the presence of the ingredient and the danger. . . . Where
warning is given, the seller may reasonably assume that it will be read and heeded; and a
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the failure to warn adequately of a defect in the product itself a basis
for imposing strict liability. The drafters of the Restatement (Second),
however, chose to provide an exemption for prescription drugs. Com-
ment k, when read together with comment j, specifically exempts pre-
scription drugs, provided adequate warning is given. While admitting
that drugs are unsafe, they are termed "unavoidably unsafe" and there-
fore not defective or unreasonably dangerous if accompanied by proper
directions and warnings. 6
3
With the inception of thepatient package insert, it becomes possi-
ble that a duty to give proper directions and warnings will now apply to
the pharmacist as well. The courts have long been hesitant to hold a
pharmacist strictly liable for the performance of his duties. Before the
PPI, the pharmacist was held not to be an insurer, making him immune
to strict liability theories of recovery and leaving him answerable only
for his negligence.' The information contained in the PPI, however,
may be viewed as the "proper directions and warnings" required by
product bearing such a warning, which is safe for use if it is followed, is not in defective
condition, nor is it unreasonably dangerous.
63. Id., comment k. Comment k provides:
There are some products which, in the present state of human knowledge, are quite
incapable of being made safe for their intended and ordinary use. These are especially
common in the field of drugs. . . . Such a product, properly prepared, and accompa-
nied by proper directions and warnings, is not defective, nor is it unreasonably danger-
ous.
For a discussion of the duty to warn regarding polio vaccines, see Note, Duty to Warn Extended to
Bystander in Close Contact to Polio Vaccinee, 29 MERCER L. REv. 643 (1978).
64. Faulkner v. Birch, 120 111. App. 281, 284-86 (1905) (instruction for plaintiff erroneous in
that it made defendant pharmacist an insurer of the accuracy of his prescriptions). See also Mc-
Leod v. W.S. Merrell, 174 So.2d 736 (Fla. 1965); Bichler v. Willig, 58 A.D.2d 331, 397 N.Y.S.2d 57
(1977); Singer v. Oken, 193 Misc. 1058, 87 N.Y.S.2d 686 (1949); Batiste v. American Home Prod.
Corp., 32 N.C. App. 1, 231 S.E.2d 269 (1977).
Very few recent cases concerning pharmacist liability have been heard. One possible expla-
nation for this is the changing system of pharmaceutical delivery. "Originally a prescription drug
could be requested from the druggist. A physician who was knowledgable in pharmacology
would tell a patient what drug might be best for him, but it was not necessary to have a prescrip-
tion to obtain many hazardous drugs." M. DIXON, DRUG PRODUCTS LIABILITY § 801, at 8-2
(1977). The pharmacist then advised among the many products available. Today's delivery sys-
tem usually requires the pharmacist to be only a "distributor of prepackaged products." Id at 8-
34. Although the duty of care is still high, there is less chance of error and therefore, less litiga-
tion. Strict liability has not been resorted to as a means of recovery in the few cases reported.
Negligence and negligence per se remain the chief causes of action with plaintiffs seldom resorting
to strict liability. See Cox v. Laws, 244 Miss. 676, 145 So. 2d 703 (1962) (deliberate violation of
statute removes bar of privity of contract); Duensing v. Huscher, 431 S.W.2d 169 (Mo. 1968)
(nonpharmacist employee negligently dispensed wrong drug, in violation of statute requiring ei-
ther a pharmacist to be on duty or notice to the patient that no pharmacist was on duty. Plaintiff
suffered brain damage and was awarded punitive damages). In McLeod v. W.S. Merrell Co., 174
So. 2d 736 (Fla. 1965), the Florida Supreme Court refused to extend strict liability to retail phar-
macists, restricting their liability to improper compounding, adulteration, and failure to use due
care in filling a prescription. The holding seems out of line with the trend toward strict liability
13
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section 402A to avoid strict liability to the patient for adverse effects
caused by the prescription. The pharmacist who fails to deliver a PPI
with the unavoidably unsafe (by definition)65 prescription medicine
may be deemed to have dispensed an unreasonably dangerous and de-
fective product. Therefore, he would become subject to the liability
without fault sanctions of section 402A, not for an error in dispensing
the prescription itself, but for nondelivery of the PPI.6 6
The Commissioner of the FDA denied that increased liability for
the dispensing pharmacist would result in all cases with the inception
of the PPI.67 Instead, he proposed that a case-by-case determination be
made according to state judicial and legislative standards.68 Consider-
ing that most states have adopted some form of strict liability pat-
terned, at least roughly, on section 402A69 and have adopted the
Uniform Commercial Code,7" strict liability for the pharmacist may be
found in the majority ofjurisdictions, despite the Commissioner's state-
ments to the contrary.7 Where the plaintiff has been harmed but the
usual defendant, the drug manufacturer, is absolved from liability be-
cause it provided the PPI to the pharmacist as required, a jury may be
inclined to find someone liable rather than allow the innocent plaintiff
to be denied recovery. It is reasonable to conclude that the pharmacist
who failed to deliver the PPI will have to bear the liability. Of course,
if the pharmacist does deliver a PPI as required, and the manufacturer
has provided adequate warnings to the prescribing physician, section
402A may work against the plaintiff to deny relief completely.
Causation must next be considered in determining a pharmacist's
potential liability. The problem of causation in strict liability cases has
created some confusion in the courts,72 particularly in cases involving
for retailers and has been criticized. See Comment, Torts-Strict Products Liabilitfor Retailers?,
45 WASH. L. REV. 431 (1970); Annot., 13 A.L.R. 3d 1057, 1099 (1967).
65. RESTATEMENT (SECOND) OF TORTS § 402A, comment k, at 353 (1965).
66. For limitations to § 402A liability, see notes 71-87 infra and accompanying text.
67. 43 Fed. Reg. 4,214 (1978).
68. Id A trend in pharmacist-patient consulation seems to be emerging. In at least six states,
the legislature has included oral consulation with the patient as a mandatory step in the com-
pounding and dispensing of a prescription. See KANSAS STATE BD. OF PHARMACY RULES AND
REGS. 68-2-20(2); ME. REV. STAT. ANN. tit. 32, § 2911(1) (1978); N.J. AD. CODE §§ 13.39-6.3(b) &
13.39-8.14; N.D. CENT. CODE § 43-15-31.2 (1978); WASH. AD. CODE § 360-16-250(1); Wis. AD.
CODE PHARMACY § 1.19. See generally Valentino, Legal Implications of U.S.P. Dispensing Infor-
mation, U.S. PHARMACIST, August 1978, at 24, 28-29.
69. W. PROSSER, supra note 35, § 98, at 657-58.
70. See notes 89-129 infra and accompanying text
71. See 43 Fed Reg. 4,214 (1978).
72. "Nor, despite the manifold attempts which have been made to clarify the subject, is there
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unavoidably unsafe products such as pharmaceuticals. 73 The Restate-
ment (Second) requires only actual, not proximate, causation under
section 402A, 7  but many courts continue to include proximate causa-
tion as an element of strict liability." Causation required in pharma-
ceutical cases should be limited to that postulated by the Restatement
(Second) in section 402A. With the limitations placed upon section
402A by comment k, the legal cause required for drug products liability
is that the injuries flow from a breach of the duty to warn of the danger
which caused the injury. If the patient would have continued taking
the prescription drug after having been warned of the possible adverse
reactions, the legal cause of the harm is insufficiently related to the
pharmacist to hold him liable even if no warning was given. An
Oklahoma case, Cunningham v. Charles Pfizer & Co.,76 held that prov-
ing merely that the polio vaccine in question was the cause in fact of
the plaintiff's injury was not enough. Not only must it be established
that the vaccine caused the injury, but it must also be shown that, had
an adequate warning been given to the plaintiff, he would not have
taken the drug.77
The Cunningham test for causation appears to bring the doctrine
of informed consent from the operating room into the pharmacy.78
The plaintiff must prove "that had the needed disclosures been made,
yet any general agreement as to the proper approach." W. PROSSER, supra note 35, § 41, at 236,
and articles cited.
73. See, e.g., Parke, Davis & Co. v. Stromsodt, 411 F. 2d 1390 (8th Cir. 1969) (drug was
probable cause of injuries as illicited by medical testimony under North Dakota law). See also
Rexall Drug Co. v. Nihill, 276 F.2d 637 (9th Cir. 1960) (applying North Dakota and California
law); Carmichael v. Reitz, Searle & Co., 17 Cal. App. 3d 958, 95 Cal. Rptr. 381 (1971). See
generally Rheingold, The Expanding Liability ofthe Product Supplier: A Primer, 2 HOFSTRA L.
REv. 521, 547-48 (1974); Note, Unavoidably Unsafe Drugs-An Oklahoma Modfication, 29 OKLA.
L. REv. 252, 258-59 (1976).
74. See generally RESTATEMENT (SECOND) OF ToRTS § 402A(l), at 348 (1965). See also
Maleson, Neghgence Is Dead But Its Doctrines Rule Usfrom the Grave A Proposal To Limit De-
fendant's Responsibilities in Strict Products Liability Actions Without Resort to Proximate Cause, 51
TEMP. L.Q. 1 (1978).
75. See Basko v. Sterling Drug, Inc., 416 F.2d 417 (2d Cir. 1969). See also Comment, Strict
Products Liability. The Irrelevance of Foreseeability and Related Negligence Concepts, 14 TULSA
L.J. 338, 360 n.112 (1978).
76. 532 P.2d 1377 (Okla. 1974).
77. Id at 1382. The court went on to state, however, that plaintiffwas entitled to a rebuttable
presumption that the patient would have heeded any warning which might have been given. Di-
rect evidence on this point was not required, following the holding of Reyes v. Wyeth Laborato-
ries, 498 F.2d 1264 (5th Cir. 1974). Receipt of the insert also presumes that the patient has read
the insert. 532 P.2d at 1382.
78. Mr. Justice Cardozo first commented on what evolved into the doctrine of informed con-
sent in Schloendorff v. Society of N.Y. Hosp., 211 N.Y. 125, 105 N.E. 92 (1914), by stating that
"[elvery human being of adult years and sound mind has a right to determine what shall be done
with his own body. ... Id. at 129, 105 N.E. at 93
[Vol. 14:590
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his course of conduct would not have included the [drug] therapy
which resulted in his injury."7 9  In other words, had the patient been
told what effects the particular drug might cause, a different course of
action would have been chosen. 0 This is especially true with regard to
contraindications8 of a drug. For example, a patient, knowing that he
is hypersensitive to penicillin, is given a prescription for Keflex, an an-
tibiotic similar to penicillin which may cause cross-sensitivity reactions
in patients also sensitive to penicillin. Upon reading the contraindica-
tion information contained in a Keflex PPI, the patient would be
alerted to the danger and another antibiotic could be prescribed. If,
however, the pharmacist omitted the PPI from the prescription, the pa-
tient would be unaware of the contraindication (assuming the physi-
cian had not inquired before prescribing, which is a separate cause of
79. Note, Unavoidably Unsafe Drugs-An Oklahoma Modcation, 29 OKLA. L. REv. 252,
258 (1976). See also Gobbs v. Grant, 8 Cal. App. 3d 229, 502 P.2d 1, 104 Cal. Rptr. 505 (1972);
Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972); Funke v. Dieldman, 212 Kan. 524, 512 P.2d
539 (1973); Trogun v. Fruchtman, 58 Wisc. 2d 569, 207 N.W.2d 297 (1973); Gravis v. Parke, Davis
& Co., 502 S.W.2d 863 (Tex. Civ. App. 1973). For a general discussion of informed consent as
applied to the physician in a medical malpractice setting, see M. DIXON, supra note 64, § 7.23, at
7-109 to 7-113; Markham, The Doctrine of Informed Consent-Fact or Fiction?, 10 FORUM 1073
(1975); Plant, Decline of Informed Consent, 35 WASH. & LEE L. REV. 91 (1973); Seidelson, Medical
Malpractice: Informed Consent in "Full Disclosure" Jurisdictions, 14 DUQ. L. REV. 309 (1976);
Comment, Who's Afraid of Informed Consent, An Affirmative Approach to the Medical Malpractice
Crisis, 44 BROOKLYN L. REV. 241 (1978); Note, Informed Consent Liability, 26 DRAKE L. REV. 696
(1977); Note, Evolution of the Doctrine ofInformed Consent, 12 GA L. REV. 581 (1978); Comment,
Informed Consent and the Patient's Right to Say "No", 6 Loy. L.A.L. REV. 384 (1973); Comment,
New Trends in Informed Consent, 54 NEBR. L. REV. 66 (1975); Comment, A New Standard of
Informed Consent in Medical Malpractice Cases-The Role of the Expert Witness, 18 ST. Louis
U.L.J. 256 (1973).
Informed consent and the delivery of the PPI present questions which could possibly change
the status of health care delivery today. First, after having been given a prescription by the physi-
cian following a thorough examination, would the patient rely on the PPI and forego the prescrip-
tion treatment or instead rely on the physician's knowledge and authority that the physician-
patient relationship carries with it? Second, will health care suffer if a PPI does promote a recon-
sideration of prescription drug therapy by the patient? "Doctors believe that patients are neither
emotionally nor intellectually equipped to play a significant role in decisions affecting their medi-
cal fate, that they must be guided past childish fears into 'rational' therapy, and that disclosures of
uncertainty, gloomy prognosis, and due risks often seriously undermine cure." Katz, Informed
Consent-A Fairy Tale? Law's Vsion, 39 U. PITT. L. REV. 137, 148 (1977). "We [the medical
profession] are all committed to providing patients with considerate and respectful care, compe-
tent medical advice, high quality medications,. . . and as much information as it is reasonably
possible to convey with regard to both treatment and illness." Guarino, Patient Package Inserts,
34 FoOD-DRuG-CosM. L.J. 116 (1979). The questions of patient rights, FDA regulations, and the
physician are fully discussed, against the backdrop of the Laetrile issue, in Note, Freedom of
Choice in Medical Treatment: Reconsidering the Efficacy Requirement of the FDCA, 9 Loy. CHI.
L.J. 205 (1977).
80. See generally Hirsch, Patient Package Inserts, 6 MED. L.J.2d 227 (1978).
81. A contraindication is an absolute warning that the drug must not be used in certain pa-
tients, for example, patients with a known hypersensitivity to the drug.
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action)82 and would therefore be unaware that he could possibly suffer
an allergic, often fatal, anaphylactic reaction for which the pharmacist
could be held liable.
The pharmacist would not be liable in tort for nondelivery of a
PPI if his omission was not the legal cause of the patient's injury. A
classic example would arise with failure to deliver a PPI with a pre-
scription of an oral contraceptive. While the pharmacist might be lia-
ble if a patient with a history of thrombophlebitis 83 developed a clot
after taking the new prescription without adequate patient warning, he
would not be liable if the patient became pregnant while taking the pill.
The pregnancy could not be viewed as a result of the pharmacist's fail-
ure to deliver the PPI.84
The limitation of foreseeability has some bearing on the extent of
the pharmacist's liability.8" When the consequences of the act (or in
the pharmacist's case, the omission) could not reasonably be antici-
pated, no legal causation exists, and there can be no liability. Though
difficulties with the language persist, foreseeability can best be defined
here as liability "only if the harm suffered is the 'natural and probable'
consequence of. . . [the pharmacist's] act."86 Prosser defines natural
as being intended to "refer to consequences which are normal, not ex-
traordinary, not surprising in the light of ordinary experience. Proba-
ble, if it is to add anything to this, must refer to consequences which
were to be anticipated at the time of the defendant's conduct."87 Fore-
seeability as a limiting factor can best be demonstrated in the example
above. When the pharmacist dispenses a supply of oral contraceptives
82. See, e.g., Rotan v. Greenbaum, 273 F.2d 830 (D.C. Cir. 1959) (physician held liable for
death resulting from anaphylactic reaction to penicillin injection); Dickens v. Everhart, 284 N.C.
95, 199 S.E.2d 440 (1973) (standard of care of physician extends to selection and use of drugs and
knowledge of dangers inherent in their use).
83. Thrombophlebitis is a listed contraindication in the presently required PPI labeling. 21
C.F.R. § 301.501(a) (1978). See App. B. It has been held, however, that if the patient knew of the
contraindication and did not inform his prescribing physician, the physician would not be liable
for adverse effects. Vaughn v. G.D. Searle & Co., 272 Or. 367, 536 P.2d 17, cert. denied, 423 U.S.
1054 (1975).
84. In an action against the manufacturer of an oral contraceptive, it was held that "manu-
facturers of products are not liable. . . to persons, who, having taken or received drugs, contract
that which the drug was designed to prevent. . . ." Whittington v. Eli Lilly & Co., 333 F. Supp,
93, 100 (S.D.W. Va. 1971).
85. W. PROSSER, supra note 35, § 43, at 250. See Polelle, The Foreseeablliy Concept and
Strict Products Liability: The Odd Couple of Tort Law, 8 RUT.-CAM. L.J. 101 (1976); Comment,
Strict Products Liability The Irrelevance of Foreseeability and Related Negligence Concepts, 14
TULSA L.J. 338 (1979).
86. W. PROSSER, supra note 35, § 43, at 252.
87. Id
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without delivering a PPI as well, the risk of developing thrombophlebi-
tis in a sensitive patient is natural and probable and, hence, a foresee-
able consequence of his omission. By no stretch of a court's
imagination could a patient's pregnancy be termed a natural and prob-
able consequence of his failure to deliver the PPI. 88
B. Breach of Warranty
The omission of a PPI may also impose liability upon the dispens-
ing pharmacist in the form of a warranty action, a relief that orginated
in tort89 and has since been written into most state codes through the
Uniform Commercial Code (U.C.C.). This action, which bases relief
on the express or implied representations by the manufacturer or the
seller of goods to the purchaser, approaches strict liability and indeed
88. Pregnancy would be a foreseeable consequence for which the pharmacist is liable if he
failed to dispense the oral contraceptive prescribed and, instead, mistakenly dispensed some other
drug. Troppi v. Scarf, 31 Mich. App. 240, 187 N.W.2d 511 (1971) (pharmacist may be required to
make child support payments).
89. A more notable example of legal miscegenation could hardly be cited than that
which produced the modem action for breach of warranty. Originally sounding in tort,
yet arising out of the warrantor's consent to be bound, it later ceased necessarily to be
consensual and at the same time came to lie mainly in contract.
Note, Necessit' for Privily of Contract in Warranties by Representation, 42 HARV. L. REV. 414, 414-
15 (1929) (citations omitted).
The action of implied warranty began in tort as a means of recovery against the marketing of
defective food products, although throughout the common law the seller of food and drink pos-
sessed a special, but fluctuating, responsibility. See Cotton, A Note on the Civil Remedies ofInjured
Consumers, 1 L. & CONTEMP. PROB. 67 (1933).
With the coming of the Industrial Revolution and its accompanying accentuation of
individualism, caveat emptor replaced the doctrine of the common calling, especially in
American courts, and protection for consumers of food and drugs was a matter of excep-
tion to be granted guardedly. Thus, though Blackstone had recognized an implied war-
ranty of fitness where food was sold, the Massachusetts court in 1813 interpreted him to
mean this to apply only where a dealer knew that he was selling impure food, and dis-
guised it, a construction which appears to unduly limit Blackstone's text.
Id at 68 (emphasis in original) (citations omitted). Nazetti v. Armour & Co., 75 Wash. 622, 135 P.
633 (1913), became the first case to discard the necessity of contract and the steady march was on
to hold sellers of defective food and drink strictly liable. W. PROSSER, supra note 35, § 97, at 653.
For a detailed development of the trend from warranty (requiring contract) to strict products
liability, see Prosser, The Assault Upon the Citadel (Strict Liability to the Consumer), 69 YALE L.J.
1099 (1960).
Items for intimate bodily use, such as cosmetics, became the next group of products to which
an implied warranty was extended until, in 1958, "the Michigan court found a warranty, without
privity and without negligence, of cinder building blocks when the user's home collapsed." W.
PROSSER, supra note 35, at 654 (citing Spence v. Three Rivers Builders & Masonry Supply, Inc.,
353 Mich. 120, 90 N.W.2d 873 (1958)). Other products quickly followed, and privity is not cur-
rently required in most jurisdictions in an action of implied warranty. The warranty action has
completed its full circle from tort to contract and back again. See Prosser, The Fall ofthe Citadel
(Strict Liability to the Consumer), 50 MINN. L. REy. 791 (1966). The remainder of this article will
deal with the implied warranty of merchantability under the Uniform Commercial Code as an
alternative theory of recovery against the dispensing pharmacist.
18
Tulsa Law Review, Vol. 14 [1978], Iss. 3, Art. 6
https://digitalcommons.law.utulsa.edu/tlr/vol14/iss3/6
TULSA LAW JO UR AAL [Vol. 14:590
has been viewed as an intermediate step between negligence and pure
strict liability.90 Though the action had its origin in tort and has re-
tained some of its tort character, 9' contract principles as governed by
the U.C.C. provide the primary basis of recovery. This is true even
though many courts have returned to tort principles to escape the har-
sher provisions required by the U.C.C. 92 By examining the warranty
provisions of the U.C.C. 93 and by applying them to the requirements
and purposes of the FDCA, it will be shown that the PPI may allow
additional theories of recovery against the dispensing pharmacist that
would have been unavailable before a PPI was required.
The pharmacist, as a prescription drug dispenser, has historically
been liable for breach of warranty even when the rule of caveat emptor
flourished.94 The pharmacist has been held to warrant "the good quali-
ty of the drug sold; that the article is of the kind he contracted [through
the prescription form presented by the patient to the pharmacist] to sell;
and, as to sale of a prescription, that he used due and proper care and
skil."9  The "good quality of the drug sold" requirement has been
modified and expanded into the U.C.C. article 2 requirement of
merchantability of goods.96 For purposes of this discussion, it will be
assumed that the sale of a prescription is a sale of goods and not of
services.97 Because the pharmacist is a "merchant with respect to goods
90. W. PROSSER, supra note 35, § 97.
91. Id at 654. See note 89 supra.
92. W. PROSSER, supra note 35, § 97, at 655. See notes 113-24 infra and accompanying text.
93. U.C.C. §§ 2-313, 2-314.
94. Jacobs Pharmacy Co. v. Gibson, 116 Ga. App. 760, -, 159 S.E.2d 171, 173 (1967). See
also note 89 supra.
95. Jacobs Pharmacy Co. v. Gibson, 116 Ga. App. 760,-, l9 S.E.2d 171, 173 (1967).
96. U.C.C. § 2-314. Section 2-314 provides:
(1) Unless excluded or modified (Section 2-316), a warranty that the goods shall be
merchantable is implied in a contract for their sale if the seller is a merchant with respect
to goods of that kind. Under this section the serving for value of food or drink to be
consumed either on the premises or elsewhere is a sale.
(2) Goods to be merchantable must be at least such as
(a) pass without objection in the trade under the contract description; and
(b) in the case of fungible goods, are of fair average quality within the description;
and
(c) are fit for the ordinary purposes for which such goods are used; and
(d) run, within the variations permitted by the agreement, of even kind, quality
and quantity within each unit and among all units involved; and
(e) are adequately contained, packaged, and labeled as the agreement may re-
quire; and
(f) conform to the promises or affirmations of fact made on the container or label
if any.
(3) Unless excluded or modified (Section 2-316) other implied warranties may
arise from course of dealing or usage of trade.
97. "Outside of a few examples of what might be considered purely services, in most cases
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of that kind [prescription drugs and medicines]," 98 an implied warranty
is created by the sale of the prescription to the patient.99 For goods to
be merchantable, they must be "adequately contained, packaged, and'
labeled as the agreement may require."' If the PPI regulations, either
presently in force' or proposed, 0 2 constitute the required agreement,
it is then possible that by omitting the required PPI the pharmacist has
dispensed an inadequately labeled product.
Thus, by the operation of U.C.C. section 2-314(2)(e), the pharma-
cist has breached an implied warranty of merchantability for which he
may be liable. The agreement is between the pharmacist and the pa-
tient for U.C.C. purposes, but the implied warranty is formed when
section 2-314 of the U.C C. is read together with section 352 of the
FDCA. Thus, the agreement implies to the patient that the pharmacist
will fill the prescription in accordance with all applicable pharmacy
regulations. The Official Comments to section 2-314103 provide that
sub-paragraph (e) "applies only where the nature of the goods and of
the transaction requires a certain type of. . . label."'" Section 352(f)
pharmacists services will entail the sale of a product and warranty law will apply:' C. DEMARCO,
PHARMACY AND THE LAW 229 (1975). This is to be contrasted with the controversy found in the
blood transfusion/serum hepatitis cases where the transfusion was held to be a service and not the
sale of a product. See Perlmutter v. Beth David Hosp., 308 N.Y. 100, 123 N.E.2d 792 (1954).
The art of healing frequently calls for a balancing of risks and dangers to a patient.
Consequently, if injury results from the course adopted, where no negligence or fault is
present, liability should not be imposed upon the institution or agency actually seeking
to save or otherwise assist the patient.
Id at 107, 123 N.E.2d at 795. The idea of a blood transfusion as a sale did not emerge until 1966
in Community Blood Bank, Inc., v. Russell, 196 So. 2d 115 (Fla. 1967), which involved a commer-
cial blood bank as compared to a hospital. A hospital was first found strictly liable for serum
hepatitis transmitted by a transfusion in Cunningham v. MacNeal Memorial Hosp., 47 Ill 2d 443,
266 N.E.2d 897 (1970). See also Schmaltz v. Saint Luke's Hosp., 33 Colo. App. 351, 521 P.2d 787
(1974). See generally Comment, Blood Transfusions and the Transmission a/Serum Hepatitis: The
Needfor Statutory Re/orm, 24 AM. U.L. REv. 367 (1975); Comment, Products Liability-Blood
Transfsions-"Implied Warranty"4ction Against Blood Suppliers Requires Showing o/Detectable
De/ect and Negligence, 3 FLA. ST. L. REv. 483 (1975).
98. U.C.C. § 2-314(1) (1972 version).
99. The warranty liability has been limited to drugs that are compounded by the pharmacist
personally and unmerchantable drugs that have expired or decomposed and are nevertheless dis-
pensed. The liability has never been applied to an adverse effect caused, not by some act or
omission of the pharmacist, but by the drug itself. McLeod v. W.S. Merrell Co., 174 So. 2d 736
(Fla. 1965) (pharmacist would not be liable for patient's adverse effect when the prescription was
filled precisely in accordance with the doctor's order and manufacturer's directions). See also
Batiste v. American Home Products Corp., 32 N.C. App. 1, 231 S.E.2d 269 (1977).
100. U.C.C. § 2-314(2)(e) (1972 version).
101. 21 C.F.R. § 310.501(a) (1978).
102. See note 6 supra and accompanying text.
103. U.C.C. § 2-314, comment 10 (1972 version).
104. Id
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of the FDCA, as amended by section 310.501(a), 0 requires a label
giving directions and warnings, in other words a PPI, to avoid mis-
branding. The U.C.C. imposes an obligation on the seller "not to de-
liver mislabeled articles."'1 6 Reading these two provisions together
indicates that liability may be imposed on a pharmacist for delivery of
a mislabeled prescription under a theory of breach of an implied war-
ranty of merchantability.
Reddick v. White Consolidated Industries, Inc. ' 7 addressed the
question of merchantability as applied to an instruction manual accom-
panying a gas heater and is instructive by analogy. The plaintiffs
claimed that the instructions supplied were inadequate, and that as a
direct result of this defect the heater was improperly installed, causing
asphyxiation. In deciding the implied warranty question, the district
court had to determine if the instruction manual could be classified as a
"label" within the meaning of the U.C.C. After examining the FDCA
definition of "label,"'0 8 the court held that the manual was not a label
under the FDCA; therefore, the U.C.C implied warranty of
merchantability would not apply.' 9 The FDCA defines labeling as
"all. .. written, printed, or graphic matter (1) upon any article or any
of its containers or wrappers, or (2) accompanying such article."' I10 It
seems clear that a PPI is to be included as labeling under the FDCA;
therefore, the U.C.C. implied warranty of merchantability would apply
to the PPI, unlike the instruction manual in the Reddick case.
The plaintiffs in Reddick recovered, however, because the court
applied the second form of implied warranty, that of fitness for a par-
ticular use.Il "If a manufacturer furnishes instructions as to a manner
105. 21 C.F.R. § 310.501(a) (1978).
106. U.C.C. § 2-314, comment 10 (1972 version).
107. 295 F. Supp. 243 (S.D. Ga. 1969).
108. See United States v. 24 Bottles, 338 F.2d 157, 158 (2d Cir. 1964).
109. 295 F. Supp. at 249-50.
110. 21 U.S.C. § 321(m) (1976) (emphasis supplied). A label is defined as
a display of written, printed, or graphic matter upon the immediate container or any
article; and a requirement made by or under authority of this chapter that any word,
statement, or other information appear on the label shall not be considered to be com-
plied with unless such word, statement, or other information also appears on the outside
container or wrapper, if any there be, of the retail package of such article, or is easily
legible through the outside container or wrapper.
Id § 201(k). See generally C. DEMARCO, supra note 97, at 127.
111. 295 F. Supp. at 250. The implied warranty of fitness for a particular use is found in
U.C.C. § 2-315 (1972 version).
Section 2-315 provides:
Where the seller at the time of contracting has reason to know any particular pur-
poses for which the goods are required and that the buyer is relying on the seller's skill or
[Vol. 14:590
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in which a product is to be used, the consumer is entitled to think that
so used it will not injure him. There is an implied warranty that the
goods are fit for that particular use.""' 2 A PPI should not subject a
pharmacist to liability if the drug does not act as intended. The im-
plied warranty of fitness for a particular purpose should apply to the
physician or manufacturer because the patient/buyer is not relying on
the pharmacist/seller's skill or judgment, but "on the skill and judg-
ment of the physician, the person who chooses the prescription." 3 In-
stead, only the warranty of merchantability would apply to the
pharmacist for dispensing a misbranded prescription.
Using a contractual theory of implied warranty under the U.C.C.
presents problems that a tort action does not. The U.C.C. requires the
buyer to give notice to the seller within a reasonable time after he knew
or should have known of the breach." 4 Additionally, the U.C.C. al-
lows a disclaimer of all express or implied warranties to be effective.
The implied warranty of merchantability may be disclaimed "by ex-
pressions like 'as is,' 'with all faults' or other language which in com-
mon understanding calls the buyer's attention to the exclusion of
warranties. . . ."' '" If such terms are not used, specific requirements
must be met, including conspicuous language (if in writing) mentioning
merchantability. The PPI" 6 contains "no reference to 'as is,' 'with all
faults' or other common commercial terms synonomous with dis-
judgment to select or furnish suitable goods, there is. . . an implied warranty that the
goods shall be fit for such purpose.
See Corman, Implied Sales Warrantyfor Fitnessfor Particular Purpose, 1958 Wis. L. REV. 219;
Note, Commercial Law-Implied Warranties Under the Uniform Commercial Code-The Implied
Warrant of Fitnessfor a Particular Purpose, 10 WAKE FOREST L. REV. 169 (1974). For a discus-
sion of implied warranties in general as applied to suppliers of services, see Greenfield, Consumer
Protection in Service Transactions-Implied Warranties and Strict Liability in Tort, 1974 UTAH L.
REV. 661; Singal, Extending Implied Warranties Beyond Goods: Equal Protection/or Consumers of
Services, 12 NEw ENG. L. REV. 859 (1977).
112. 295 F. Supp. at 250.
113. Frey, The Pill and the Code, 15 J. FAM. L. 1 (1976). See generally Carleton, Physician
Liabili'for Adverse Drug Reactions, 24 MED. TRIAL TECH. Q. 184 (1978); Comment, Prescriotions
as an Extension of the Doctor-Patient Relationship, 22 CLEV. ST L. REV. 549 (1973); Comment,
Liabiiof'or Failure ofBirth Control Methods, 76 COLUM. L. REv. 1187(1976). See also Incollingo
v. Ewing, 444 Pa. 263, 282 A.2d 206 (1971) (physician held liable for repeated administration of
Chloromycetin without adequate testing).
114. U.C.C. § 2-607(3) (1972 version). New York, however, has held that goods sold for
human consumption are not subject to § 2-607. See Fischer v. Mead Johnson Laboratories, 41
A.D.2d 737, 341 N.Y.S.2d 257 (1973). Illinois has upheld the notification requirement saying that
the plain meaning of the statute requires such an interpretation. Berry v. G.D. Searle & Co., 56
I11. 2d 548, -, 309 N.E.2d 550, 554-55 (1974).
115. U.C.C. § 2-316(3)(a) (1972 version).
116. See App. A&B.
1979]
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claimer. Nor is there mention of merchantability." '" 7 Thus, it appears
that the PPI is not a disclaimer of liability, but is instead only a warn-
ing, with no effect on U.C.C. liablity."l8 In any event, the nondelivery
of a PPI could result in liability under any of the above theories of
recovery, since no label that could be classed as either a warning or a
disclaimer was given to the patient.
Section 2-715 of the U.C.C. expressly provides for the recovery of
consequential damages including injury to "person or property proxi-
mately resulting from any breach of warranty."" 19 This raises the ques-
tion of legal causation that was first presented in the discussion of the
duty to warn liability concept.1 20 The comments to section 2-715 define
this causation factor somewhat differently than the standard tort usage:
Where the injury involved follows the use of goods without
discovery of the defect [in this case, the non-delivery of the
PPI, resulting in unmerchantability of the prescription] caus-
ing the damage, the question of "proximate cause" turns on
whether it was reasonable for the buyer to use goods without
such inspection as would have revealed the defects. If it was
not reasonable for him to do so, or if he did in fact discover
the defect prior to his use, the injury would not proximately
result from the breach of warranty. 12
Where there is nondelivery of the PPI causing the prescription to
be misbranded and therefore unmerchantable, it must also be shown
that the patient would not reasonably have been expected to inspect the
prescription in order to discover the defect.122 This theory of causation
is a difficult one for the pharmacist to overcome. The defect caused by
the misbranding is one brought about by omission, not by an overt,
physical act. Therefore, unless the patient had received the drug before
and was expecting to receive a PPI and did not, there is nothing unu-
sual about the prescription that would put the patient on notice of the
hidden defect. The patient must also show that the nondelivery of the
117. Frey, supra note 113, at 19. For a general discussion of warranty disclaimers, see Mc-
Nichols, Who Says That Strict Tort Disclaimers Can Never Be Effective? The Courts Cannot Agree,
28 OKLA. L. REV. 494 (1975); Parker, The Warranty Disclaimer v. Manufacturers' Products Liabil-
ity-Steiner Aero AB v. Page Airmotive, Inc.: Did the Tenth Circuit Bury the Disclaimer Alive?, 10
TULSA L.J. 612 (1975); Weintraub, Disclaimer of Warranties and Limitations of Damages for
Breach of Warranty Under the U. CC, 5 Tax. L. REv. 60 (1974).
118. See Frey, supra note 113, at 18-19.
119. U.C.C. § 2-715(2)(b) (1972 version).
120. See notes 39-87 supra and accompanying text.
121. U.C.C. § 2-715, comment 5 (1972 version).
122. See Dunlap v. Oakliff Pharmacy Co., 288 S.W. 236 (Tex. Civ. App. 1926) (layman will
not appreciate that substituted drug would not have same label).
[Vol. 14:590
23
Walker: The Patient Package Insert and Pharmacist Liability
Published by TU Law Digital Commons, 1978
PHA.RMA CIST LIABILITY
PPI was the proximate cause of the injury itself,'2 3 in addition to show-
ing that it was reasonable for him to take the prescription without in-
specting for defects. It becomes more difficult for the patient to recover
under the U.C.C. for consequential damages in that certain require-
ments must be complied with in addition to proximate causation, most
notably, that of notice of the breach.' 24 While the requirement of no-
tice has been modified and extensively limited by some courts, 2 5 it still
presents a barrier to recovery for the unknowing plaintiff. The statute
of limitations in a warranty action may cause disadvantages as well.
Though longer '26 than most two-year tort statutes, the cause of action
accrues when tender of delivery is made. 27 Thus, it is possible that the
plaintiff's cause of action may be barred before any injury has oc-
curred.' 28 On the other hand, if the particular jurisdiction recognizes
liability under section 402A,
a plaintiff who is injured more that four years after the sale of
the defective product, although barred from recovery in a
breach of warranty action pursuant to the Code, will never-
theless have two years to bring an action based on strict tort
liability, provided she can show that the defective product was
unreasonably dangerous as required under 402A.'29
IV. CONCLUSION
Once the pharmacist was liable to the patient only for negligent
performance of his duties.' 30 It now appears possible that FDA and
congressional action to require patient labeling for most drugs will in-
123. One causal problem relates to the statistical probability for injury due to the pill.
Women may suffer heart attacks and strokes whether or not they use oral contraceptives.
The pill only increases the rate at which these event occur. Must the injured consumer
establish that her stroke was not the one in eight which still would have occurred had she
not taken the pill? This issue has not reached the reported decisions. It would seem,
however, that the causal chain must be established with more information than merely
the higher incidences of heart attack and stroke due to the pill.
Frey, supra note 113, at 16 n. 11. See generally, J. WHITE & R. SUMMERS, HANDBOOK OF THE
LAW UNDER THE UNIFORM COMMERCIAL CODE 296 (1972).
124. See Frey, supra note 113, at 10-11.
125. See Fischer v. Mead Johnson Laboratories, 41 A.D.2d 737, 341 N.Y.S.2d 257 (1973).
Contra, Berry v. G.D. Searle & Co., 56 Ill. 2d 548, 309 N.E.2d 550 (1974).
126. U.C.C. § 2-725(1) (1972 version) prescribes a period of four years from the time tender of
delivery is made.
127. U.C.C. § 2-725(2) (1972 version).
128. Frey, supra note 113, at 10. Compare the U.C.C. accrual of a cause of action with that
under a tort statute requiring the cause of action to begin when the injury was sustained. See, e.g.,
ILL. REV. STAT. ch. 83, § 15 (1966).
129. Frey, supra note 113, at 10 (citation omitted).
130. See notes 39-59 supra and accompanying text.
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crease the liability of the pharmacist up to and including strict liability.
In this age of awareness and consumer reform, perhaps this is a lauda-
ble development. As before, the pharmacist must still practice with a
high degree of skill and competency. The PPI requirement will do
nothing to change this standard of care. Now, however, a pharmacist
must also dispense additional labeling to make the prescription com-
plete. New and efficient distribution systems must be developed by
each pharmacy to insure that a PPI is delivered with each prescription
to reduce exposure to liability for nondelivery.
If the PPI will act as a means of educating the patient about his
drug regimen and encourage him to ask meaningful questions of both
the physician and the pharmacist, the labeling will have served its pur-
pose admirably and will enhance medical health care dramatically.
Physicians will be more mindful of what they prescribe, and pharma-
cists will be able to provide a more professional service to the general
public. Though it may be doubted that the Commissioner of the FDA
intended such a result when the PPI was proposed, the increased liabil-
ity has a sound, theoretical basis in the law. Whether a court would use
the PPI as grounds for imposing liability remains to be seen. A number
of factors may control the outcome, particularly the relationship be-
tween the injury and the omission by the pharmacist as well as the
availability of a more desirable defendant such as the pharmaceutical
manufacturer. It appears, however, that potential liability based on the
PPI will be available when the issue comes to court.
Craig Harman Walker
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APPENDIX A
Required Labeling for the Patient Taking
Pharmaceuticals Containing Estrogen
21 C.F.R. § 310.515 (1978)
WHAT YOU SHOULD KNOW ABOUT ESTROGENS
Estrogens are female hormones produced bytheovanes. The ovanes make
evscral ctferent kinds of estrogens In addtion, scientists have been able to
mate a vanety of synthetic estrogens As far as we know, all these estrogens
have nmlar properties and therefore much the same usefulness. side effects.
and risks This leaflet Is intended to help you understand what estrogens are
used for, the niis involved in their use, and how to use them as safely as
pos-o
Th31oaflet includes the most important information about estrogens, but not
all tho information If you want to know more. you should ask your doctor for
more intormabon or ;,-ou can ask your doctor or pharmacist to let you read the
pac-ago insert prepared for the doctor.
USES OF ESTROGEN
THERE IS NO PROPER USE OF ESTROGENS INA PREGNANT WOMAN,
Estrogens are prescnbed by doctors for a number of purposes, including:
I To prode estrogen during a penod of adjustment when a woman's ova-
rics stop producing a ma;onty of her estrogens, in order to prevent certain un-
comfortable symptoms oi estrogen deficiency (rfth the menopause. wnhch
gcnrasly occurs balveen the ages of 45 and 55. women produce a much
sraller amount of estrogens)
2 To prevent symptoms of estrogen deficency vhen a woman's ovanes
have b 'en removed surg cally before the natural menopause.
3 To prevent pregnancy (Estrogens are given along vith a progestogen.
anotti r female horione; thesoe combinations are called oral contraceptives or
b rth control plHs Patient label ng is available towomen takng oral contracep-
tioS, and they . l not be discussed in this leaflet)
4 To treat certain cancers in vomen and men
5 To prevent patnful s elng of the breasts after pregnancy in women who
choos'e not to nurse their bab es
ESTROGENS IN THE MENOPAUSE
tn the natural course of their ves. all vomen eventually expenence a de-
creasen estrogen product on This usually occurs bet een ages 45 and 55 but
may occur earl or or later Sometmes the ovanes may need to be removed
beforc natural menopause by an operation. producing a "surg'sat menopause."
Whnthe amount of estrog onin the blood begins to decrease, many-onmen
may develop typ cat symptoms feelrogsof warmth m the face, neck, and chest
or cuddrn intense episodes of heat and sw;eating throughout the body (called
hottlahvs *or hotflushes) Thesesymptomsaresometmesveryunccmfort-
absc, Some women may also develop changes in the vagina (called atrophic
vag
, 
nit. ) which cause discomfort, especially dunng and after intercourse.
Etrogens can be prescrbedto treat these symptoms of the menopause It is
estimated that consderably more than half of all v.omen undergoeg the meno-
paus,) have only mild symptoms or no symptoms at all and therefore do not
need estrogens Other v.omen may need estrogens for a few months. while
their bod oS adust to to:.,r estrogen levels Sometimes the need wil be for
p rl0oo longer than six months- In an attempt to avoid overstmulation of the
uterus (. oob). estrogens are usually given cycically dunng each month of use.
such as three v.eks of pills folloed by one v.eek va thout p-l~s
Sormnotmes vomen experence nervous symptoms or depreeson dunng
menopaus There is no evidence that estrogens are effective for such symp-
toms vthout associated vasomotor symptoms In the absence of vasomotor
symptoms, estrogens should not be usedto treat nervous symptoms, although
othcr treatment may be needed
You may hase heard that taking estrogens for long periods (years) after the
menopause v.11 keep your skin soft and supple and keep you feeling young
There is no evidence that this is so. hoeever. and such long-term treatment
carries important risks
ESTROGENS TO PREVENT SWELLING
OF THE BREASTS AFTER PREGNANCY
Ittyou do notbreat-feedyour baby afterdelivery, yourbreastsmay fillup with
mik and become painful and engorged This usually begins about3 to 4 days
after dcl,"ery and may last for a fevdays to up to aweek or more. Sometimes
the d comfort is severe, but usually it is not and can be controlled by pain-
re! o,ng drugs such as aspion and by b.nelng the breasts up t ghtly. Estrogens
can be used to try to prevent the breasts from fillig up, While this treatment is
fomet mos successful, in many casesthe breasts fll up to somedegreein spite
oftroatment The dose of estrogens needed to prevent pain and swelling of the
breasts is much larger than the dose needed to treat symptoms of the meno-
paucvand this may increase your chancesof developing blood clotsin the legs
orlueg, (sce beo.s) Therefore, it is important that you discus the benefits and
the ro liso ofstrogen use "t.hyour doctor i you have decided notto breast-feed
your baby
THE DANGERS OF ESTROGENS
1. Endometnal cancer There are reports that if estrogens are used in the
postmenopausal perod for more than a year. there is an increased nob of
endometnal cancer (cancer of the lining of the uterus). Women taking es-
trogens have roughly 5 to 10 times as great a chance of getting this cancer as
women who take no estrogens. To put this another way, while a
postmenopausal woman not taking estrogens has I chance in 1,000 each year
of geMng endometnal cancer. awoman taking estrogens hasSto 10chances in
1,00Oeachyear. Forthis reasonitismportantto take estrogensonlywhen they
are really needed.
The nsk of this cancer is greater the longer estrogens are used and when
largerdoses are taken. Therefore you should not take more estrogen than your
doctor prescribes. It is important to take the lowest dose of estrogen that will
control symptoms and to take it only as long as it is needed. If estrogens are
needed for longer penods of time, your doctor aill want to reevaluate your need
for estrogens at least every six months.
Women using estrogens should report any vaginal bleeding to their doctors;
such bleeding may be of no importance, but it can be an early warning of
endometrial cancer. If you have undiagnosed vaginal bleeding, you should not
use estrogens until a diagnosis is made and you are certmn there is no
endometnal cancer.
NOTE: If you have had your uterus removed (total hysterectomy), there is no
danger of developing endometnal cancer.
2. Other possible cancers. Estrogens can cause development of other
tumors in animals, such as tumors of the breast, cervix. vagina, or liver. wohen
given for a long time. At present there is no good evidence that %vomen using
estrogen in the menopause have an increased risk of such tumors, but there is
no way yet to be sure they do not; and one study raises the possbility that use of
estrogens in the menopause may increase the rsk of breast cancer many years
later. This is a further reason to use estrogens only when clearly needed. While
you are taking estrogens, it s important that you go to your doctor at least once
a year for a phys;cal examination. Also, if members of your family have had
breast cancer or if you have breast nodules or abnormal mammograms (breast
x-rays), your doctor may wish to carry out more frequent examinations of your
breasts
3. Gallbladder disease. "/omen who use estrogens after menopause are
more lihkely todevelop gallbladder disease needing surgery than womenwhoedo
not use estrogens. Birth control pills have a similar effect.
4 Abnormal blood clothng. Oral contraceptives increase the risk of blood
clotting in vanous parts of the body. This can result i a stroke (if the clot is in the
brain), a heart attack (clot in a blood vessel of the heart), or a pulmonary
embolus (a clot which forms in the legs or pelvis, then breaks off and travels to
the lungs). Any of these can be fatal.
At this time use of estrogens in the menopause is not knovn to cause such
blood clotting, but this has not been fully studied and there could still prove to be
such a rsk. It is recommended that if you have had clottg in the legs orlungs or
a heart attackor stroke whileyou were using estrogens or birth control pills, you
should not use estrogens (unless they are being used to treat cancer of the
breastor prostate). If you have had a stroke or heart attackorif you have angina
peoctons, estrogens should be used wath great caution and only if cleary needed
(for example. if you have severe symptoms of the menopause).
The larger doses of estrogen used to prevent swelling of the breasts after
pregnancy have been reported to cause clothng in the legs and lungs.
SPECIAL WARNING ABOUT PREGNANCY
You should not receive estrogen i youare pregnant. Ifthis should occur, there
isa greater than usual chance that the developing child cll be om with a birth
defect, although the poessbility remains farly small. A femalechild may have an
increased risk of developing cancer of the vagina or cervix later in life (in the
teens or twenties). Every possible effort should be made to avoid exposure to
estrogens dung pregnancy If exposure occurs, see your doctor.
OTHER EFFECTS OF ESTROGENS
In additon to the senous known nsks of estrogens descnbed above, es-
trogens have the follo ng side effects and potential nsks:
1 Nausea and voming. The most common side effect of estrogen therapy
is nausea. Vomiting is less common.
2. Effects on breasts. Estrogens may cause breast tendemess or enlarge-
ment and may cause the breasts to secrete a liquid. These effects are not
dangerous
3. Effects on the uterus. Estrogens may cause benign fibroid tumors of the
uterus to get larger.
4. Effects on lver Women taking oral contraceptives develop on rare occa-
smons a tumor of the lver which can rupture and bleed into the abdomen and
19791
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maycause death. So far, these tumors have not been reported in women using
estrogens in the menopause, but you should report any sweilling or unusual
pain or tenderness in the abdomen to your doctor immediately.
Women with apast historyofjaundice (yeilowing of the skin and white parts of
the eyes) may geti jaundice again during estrogen use. If this occurs, stop taking
estrogens and see your doctor.
5. Other effects. Estrogens may cause excess fluid to be retained in the
body. This may make some conditions worse, such as asthma, epilepsy,
migraine, heart disease, or kidney disease.
SUMMARY
Estrogens have importantuses. but they have serious risks aswell You must
decide, with your doctor, whether the risks are acceptable to you in view of the
benefits of treatment. Except where your doctor has prescribed estrogens for
use in special cases of cancer of the breast or prostate, you should not use
estrogens if you have cancer of the breast or uterus, are pregnant, have
undiagnosed abnormal vaginal beeding. clotting in the legs or lungs, or have
IT
APPENDIX B
Required Labeling for the Patient Taking
Oral Contraceptives, 21 C.F.R. § 310.501(a) (1978)
R-643-10-00-6
Detailed Patient Labeling
ORTHO-NOVUM 1/50 0 21
Each tablet contains 1 mg norethindrone and 0.05 mg mestranol.
ORTHO-NOVUM 1/50 0 28 Day Regimen
Each yellow tablet contains 1 mg norethindrone and 0.05 mg
mestranol.
Each green tablet contains inert ingredients.
ORTHO-NOVUM 1/80 0 21
Each tablet contains 1 mg norethindrone and 0.08 mg mestranol.
ORTHO-NOVUMI/80 028 Day Regimen
Each white tablet contains 1 mg norethindrone and 0.08 rag
mestranol.
Each green tablet contains inert ingredients.
MODIORN
Each tablet contains 0.5 mg norethindrone and 0.035 mg ethinyl
estradiol.
MODICON 28 Day Regimen
Each white tablet contains 0.5 mg norethindrone and 0.035 mg
ethinyl estradiol.
Each green tablet contains inert ingredients.
ORTHO-NOVUM 2mg 0 21
Each tablet contains 2mg norethindrone and 0.10 mg mestranol.
ORTHO-NOVUM 10 mg
Each tablet contains 10 mg norethindrone and 0.06 mg mestranol.
MICRONOR
Each tablet contains 0.35 mg norethindrone.
What You Should Know About OrMl Contraceptives
Oral contraceptives ("the pill") are the most effective way (except
for sterilization) to prevent pregnancy. They are also convenient
and, for most women, free of serious or unpleasant side effects.
Oral contraceptives must always be taken under the continuous
supervision of a physician.
The information in this leaflet under the headings "Who Should
Not Use Oral Contraceptives," "The Dangers of Oral Contracep-
tives," and "How to Use Oral Contraceptives As Effectively As
Possible, Once You Have Decided to Use Them" is also applicable
when these drugs are used for other indications,
ORTHO-NOVUM 2 mg may be prescribed for you for the treatment
of hypermenorrhea.
ORTHO-NOVUM 10 mg may be prescribed for you for the treat-
ment of hypermenorrhea and endometriosis.
It is important that any woman who considers using an oral con-
traceptive understand the risks involved. Although the oral con-
traceptives have important advantages over other methods of con-
traception, they have certain risks that no other method has. Only
you can decide whether theadvantages are worth these risks. This
leaflet will tell you about the most important risks, It will explain
howyou can help your doctor prescribe the pill as safelyas possible
by telling him about yourself and being alert for the earliest signs of
trouble. And itwill tell you how to use the pill properly, so that It will
be as effective as possible. There is more detailed Information
available in the leaflet prepared for doctors. Your pharmacist can
show you a copy; you may need your doctor's help in understand-
ing parts of it.
Who Should Not Use Oral Contraceptives
A. If you have now, or have had in the past, any of the following
conditions you should not use the pill:
1. Heart attack or stroke,
2. Clots in the legs or lungs.
3. Angina pectoris.
4. Known or suspected cancer of the breast or sex organs,
5. Unusual vaginal bleeding that has not yet been diagnosed.
B. If you are pregnant or suspect that you are pregnant, do not use
the pill.
C. Cigarette smoking increases the risk of serious
adverse effects on the heartand blood vessels from
oral contraceptive use. This risk Increases with ago
and with heavy smoking (15 or more cigarettes per
day) and is quite marked in women ovar35 years of
age. Women who use oral contraceptives should
not smoke.
D. If you have scanty or irregular periods or are a young woman
without a regular cycle, you should use another method of con-
traception because, if you use the pill, you may have difficulty
becoming pregnant or may fail to have menstrual periods after
discontinuing the pill.
'JOURNAL [Vol. 14:590
had a stroke, heart attack or angina, or coltng In the logs or lungs In the past
while you were taking estrogens
You can use estrogens as safely as poss, ile by understanding that your
doctorvll require regular physical examinations while you are taking them and
all try to discontinue the drug as soon as possbe and usa the smallet dose
possib!e. Be alert for s~gns of trouble Including,
1. Abnormal bleeding from the vagfna
2. Pains in the calves or chest or sudden shortoes of breath, or coughting
blood,
3. Severe headache, dizzinss, faminass, or changes In vision.
4. Breast lumps (you should ask your doctor how to examine your own
breasts).
5. Jaundice (yellowing of the skin).
Your doctor has preocnbed this drug for you and you alone Do not givo the
drug to anyone else
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E Although it is your decision, since many risks increasewith age,
birth control pits are not recommended forwomen past the age
of 40
Deciding To Use Oral Contraceptives
If you do not have any of the conditions listed above and are think-
ing about using oral contraceptives, to help you decide, you need
information about the advantages and risks of oral contraceptives
and of other contraceptive methods as well. This leaflet describes
the advantages and rsks of oral contraceptives. Except forsteriliza-
tion, the IUD and abortion, which have their own exclusive risks,
the only risks of other methods of contraception are those due to
pregnancy should the method fail. Your doctor can answer ques-
tions you may have with respect to other methods of contracep-
tion. He can also answer any questions you may have after reading
this leaflet on oral contraceptives.
1. What Oral Contraceptives Are and How They Work. Oral
Contraceptives are of two types. The most common, often simply
called "the pill," is a combination of an estrogen and progestogen,
the two kinds of female hormones. The amount of estrogen and
progestogen can vary, but the amount of estrogen is most impor-
tant because both the effectiveness and some of the dangers of oral
contraceptives are related to the amount of estrogen. This kind of
oral contraceptiveiworks principally by preventing releaseofan egg
from the ovary. When the amount of estrogen is 50 micrograms or
more, and the pill is taken as directed, oral contraceptivesare more
than 99% effective (i.e., there would be less than one pregnancy if
100 women used the pill for one year). Pills that contain 20 to 35
micrograms of estrogen varyslightly in effectiveness, ranging from
93% to more than 99% effectiye.
The second type of oral contraceptive, often called the "mini-pill,"
contains only a progestogen. It works in part by preventing release
of an egg from the ovary but also by keeping sperm from reaching
the egg and by making the uterus (womb) less receptive to any fer-
tilized egg that reaches it. The mini-pill is less effective than the
combination oral contraceptive, about 97% effective. In addition,
the progestogen-only pill has a tendency to cause irregular bleeding
which may be quite inconvenient, or cessation of bleeding entirely.
The progestogen-only pill is used despite its lower effectiveness in
the hope that it will prove not to have some of the serious side
effects of the estrogen-containing pill (see below) but it is not yet
crtain that the mini-pill does in fact have fewer serious side effects.
Thediscussion below, while based mainlyon information aboutthe
combination pills, should be considered to apply as well to the
mini-pill.
2. Other Nonsurgical Ways to Prevent Pregnancy. As this
leaflet will explain, oral contraceptives have several serious risks.
Other methods of contraception have lesser risks or none at all.
They are also less effective than oral contraceptives, but, used
properly, may be effectiveenough for manywomen. The follovong
tab!e gives reported pregnancy rates (the number of women out of
100 who would become pregnant in one year) for these methods:
Pregnancies Per 100 Women Per Year
Intrauterine device (IUD), less than 1-6;
Diaphragm with spermicidal products (creams or jellies), 2-20;
Condom (rubber), 3-36; Aerosol foams, 2-29;
Jellies and creams, 4-36;
Periodic abstinence (rhythm) all types, less than 1-47;
1. Calendar method, 14-47;
2. Temperature method, 1-20;
3. Temperature method- intercourse only in postovulatory
phase, less than 1-7;
4. Mucus method, 1-25;
No contraception, 60-80.
The figures (except for the IUD) varywidely because peple differin
how well they use each method. Very faithful users of the various
methods obtain very good results, except for users of the calendar
method of penodicabstinence (rhythm). Except for the IUD, effec-
tive use of these methods requires somewhat more effort than
simply taking a single pill every morning, but it isan effort that many
couples undertake successfully. Your doctor can tell you a great
deal more about these methods of contraception.
3. The Dangers of Oral Contraceptives.
a. Circulatory disorders (abnormal blood clotting, heart attack,
and stroke due to hemorrhage). Blood clots (in various blood
vessels of the body) are the most common of the serious side
effects of oral contraceptives. A clot can result in a stroke (if the clot
is in the brain), a heart attack (if the clot is in a blood vessel of the
heart), or a pulmonary embolus (a clot which forms in the legs or
pelvis, then breaks off and travels to the lungsl. Any of these can be
fatal. Clots also occur rarely in the blood vessels of the eye, resulting
in blindness or impairment of vision in that eye. There is evidence
that the risk of clotting increases with higher estrogen doses. It is
therefore important to keep the dose of estrogen as low as possible,
so long as the oral contraceptive used hasan acceptable pregnancy
rateand doesn't cause unacceptable changes in the menstrual pat-
tern. Furthermore, cigarette smoking by oral contraceptive users
increases the risk of serious adverse effects on the heart and blood
vessels. This risk increases with age and with heavy smoking (15 or
-more cigarettes per day) and begins to become quite marked in
women over 35 years of age, For this reason, women who use oral
contraceptives should not smoke.
The risk of abnormal blood clotting increases with age in both users
and nonusers of oral contraceptives, but the increased risk from the
oral contraceptive appears to be present at all ages. For women
aged 20 to 44 it is estimated that about I in 2.000 using oral con-
traceptiveswill be hospitalized each year because ofabnormal clot-
ting. Among nonusers in the same age group, about 1 in 20,000
would be hospitalized each year. For oral contraceptive users in
general, it has been estimated that in women between the ages of
15 and 34 the risk of death due to a circulatory disorder is about
1 in 12,000 per year, whereas for nonusers the rate is about
1 in 50,000 per year. In theagegroup 35 to 44, therisk isestimated
to be about 1 in 2,500 per year for oral contraceptive users and
about 1 in 10,000 per year for nonusers.
Even without the pill the nsk of having a heart attack increases with
age and is also increased by such heart attack risk factors as high
blood pressure, high cholesterol, obesity, diabetes, and cigarette
smoking. Without any risk factors present, the use of oral contra-
ceptives alone may double the risk of heart attack. However, the
combination of cigarette smoking, especially heavy smoking, and
oral contraceptive usegreatly increasesthe risk of heartattack. Oral
contraceptive users who smoke are about five times more likely to
have a heart attack than users who do not smoke and about ten
times more likely to have a heart attack than nonusers who do not
smoke. It has been estimated that users between theagesof3Oand
39 who smoke have about a 1-in-1 0,000 chance each year of hav-
ing a fatal heart attack compared to about a 1-in-50,000 chance in
users who do not smoke, and about a 1-in-100,000 chance in
nonusers who do not smoke. In the age group 40 to 44, the risk is
about 1 in 1,700 per year for users who smoke compared to about 1
in 10,000 for users who do not smoke and to about 1 in 14,000 per
year for nonusers who do not smoke. Heavy smoking (about 15
cigarettes or more a day) further increases the risk. If you do not
smoke and have none of the other heart attack risk factors
described above, you will havea smaller risk than listed. If you have
several heart attack risk factors, the risk may be considerably
greater than listed.
In addition to blood-clotting disorders, it has been estimated that
women taking oral contraceptives are twiceas likelyas nonusers to
have a stroke due to rupture of a blood vessel in the brain.
One report suggests that the risk of circulatory diseases appears to
increase the longer you are on the pill and may continue after you
stop.
b. Formation of tumors. Studies have found that when certain
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animals are given the female sex hormone estrogen, which is an
ingredient of oral contraceptives, continuously for long periods,
cancers may develop in the breast, cervix, vagina, and liver.
These findings suggest that oral contraceptives may cause cancer
in humans. However, studies to date in women taking currently
marketed oral contraceptives have not confirmed that oral con-
traceptives cause cancer in humans. Several studies have found no
increase in breast cancer in users, although one study suggested
oral contraceptives might cause an increase in breast cancer in
women who already have benign breast disease (e.g., cysts).
Women with a strong family history of breast cancer or who have
breast nodules, fibrocystic disease, or abnormal mammograms or
who were exposed to DES (diethylstilbestrol), an estrogen, during
their mother's pregnancy must be followed very closely by their
doctors if theychoose to use oral contraceptives instead of another
method of contraception. Many studies have shown that women
taking oral contraceptives have less risk of getting benign breast
disease than those who have not used oral contraceptives.
Recently, strong evidence has emerged that estrogens (one com-
ponent of oral contraceptives), when given for periods of more
than one year to women after the menopause, increase the risk of
cancer of the uterus (womb). There is also some evidence that a
kind of oral contraceptive which is no longer marketed, thesequen-
tial oral contraceptive, may increase the risk of cancer of the uterus.
There remains no evidence, however, that the oral contraceptives
now available increase the risk of this cancer.
Oral contraceptives do cause, although rarely, a benign (non-
malignant) tumorof the liver. Thesetumors do notspread, but they
may rupture and cause internal bleeding, which may be fatal. A few
cases of cancer of the liver have been reported in women using oral
contraceptives, but it is not yet known whether the drug caused
them.
c. Dangers toa developingchild if oralcontrracep tivesare used in
or immediately preceding pregnancy. Oral contraceptives should
not be taken by pregnant women because they may damage the
developing child. An increased risk of birth defects, including heart
defects and limb defects, has been associated with the use of sex
hormones, including oral contraceptives, in pregnancy. In addi-
tion, the developing female child whose mother has received DES
(diethylstilbestrol), an estrogen, during pregnancy has a risk of get-
ting cancer of the vagina or cervix in her teens oryoung adulthood.
This risk is estimated to be about 1 to 4 in 1000 exposures. Abnor-
malities of the unnary and sex organs have been reported in male
offspringso exposed. It is possible that other estrogens, suchas the
estrogens in oral contraceptives, could have the same effect in the
child if the mother takes them during pregnancy.
If you stop taking oral contraceptives to become pregnant, your
doctor may recommend that you use another method of con-
traception for a short while, for example three months. The reason
for this is that there is evidence from studies in women who have
had "miscarriages" soon after stopping the pill, that the lost fetuses
are more likely to be abnormal. Whether there is an overall increase
in "miscarnage" in women who become pregnant soon after stop-
ping the pill as compared with women who do not use the pill is not
known, but it is possible that there may be. If, however, you do
become pregnant soon after stopping oral contraceptives, and do
not have a miscarriage, there does not appear to be evidence that
the baby has an increased risk of being abnormal.
d. Gallbladder disease. Women who use oral contraceptives
have a greater risk than nonusers of having gallbladder disease re-
quiring surgery. The increased risk may first appearwithin one year
of use and may double after four or five years of use.
a. Otherside effects oforalcontraceptives. Somewomen using
oral contraceptives experience unpleasant side effects. Some of
these may be temporary. Your breasts may feel tender, nausea and
vomiting may occur, you may gain or loseweight, and your ankles
may swell. A spotty darkening of the skin, particularly of the face, is
tlW JOURNAL [Vol. 14:590
possible and may persist. You may notice unexpected vaginal
bleeding or changes in your menstrual period. Irregular bleeding is
frequently seen when using the mini-pill or combination oral con-
traceptives containing less than 50 micrograms of estrogen.
More serious side effects include worsening of migraine, asthma,
epilepsy, and kidney or heart disease because of a tendency for
water to be retained in the body when oral contraceptives are used.
Other side effects are growth of preexisting fibroid tumors of the
uterus; mental depression; and liver problems with Jaundice
(yellowing of the skin). Your doctor may find that levels of sugar
and fatty substances in your blood are elevated; the long-term
effects of these changes are not known. Some women develop
high blood pressure while taking oral contraceptives, which or-
dinarily returns to the original levels when the oral contraceptive is
stopped.
Other reactions, although not proved to be caused by oral con-
traceptives, are occasionally reported. These include more fre-
quent urination and some discomfort when urinating, kidney
disease, nervousness, dizziness, some loss of scalp hair, an
increase in body hair, an increase or decrease in sex drive, appetito
changes, cataracts, and a need for a change in contact lens
prescription or inability to use contact lenses.
After you stop using oral contraceptives there may be a delay
beforeyou areable to become pregnant or before you resume hav-
ing menstrual periods. This is especially true of women who had
irregular menstrual cycles prior to the useof oral contraceptives, As
discussed previously, your doctor may recommend that you wait a
short while after stopping the pill before you try to become prg-
nant. During this time, use another form of contraception You
should consult your physician before resuming use of oral con-
traceptives after childbirth, especially if you plan to nurse your
baby. Drugs in oral contraceptives are known to appear in the milk,
and the long-range effect on infants is not known at this time. Fur-
thermore, oral contraceptives may cause a decrease in your milk
supply as well as in the quality of the milk,
4. Comparison of the Risks of Oral Contraceptives and Other
Contraceptive Methods. The many studies on the risks and
effectiveness of oral contraceptives and other methods of con-
traception have been analyzed to estimate the risk of death
associated with various methods of contraception, This risk has
two parts: (a) the risk of the method itself (e.g., the nsk that oral
contraceptives will cause death due to abnormal clotting), and
(b) the risk of death due to pregnancy or abortion in the event the
method fails. The results of this analysis are shown in the bar graph
below. The height of the bars is the number of deaths per 100,000
women each year. There are six sets of bars, each set referring to a
specific age group of women, Within each set of bars there Is a
single bar for each of the different contraceptive methods, For oral
contraceptives, there are two bars -one for smokers and the other
for nonsmokers. The analysis is based on present knowledge and
new information could, of course, alter it, The analysis show3 that
the risk of death from all methods of birth control is low and below
that associated with childbirth, except for oral contraceptives in
women over4Owhosmoke. Itshows that thelowest risk of death Is
associated with the condom or diaphragm (traditional contracep-
tion) backed up byearlyabortion in case of failure of thecondom or
diaphragm to prevent pregnancy. Also, at any age the risk of death
(due to unexpected pregnancy) from the use of traditional con-
traception, even without a backup of abortion, is generally the
same as or less than that from use of oral contraceptives,
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Figure 1. Estimated annual number of deaths associated with control of
fertility and no control per 100,000 nonsterile women, by regimen of
control and age of woman.
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How to Use Oral Contraceptives As Effectively As Possible,
Once You Have Decided to Use Them
1. What to Tell your Doctor.
You can make use of the pill as effectively as possible, by telling
your doctor if you have any of the following:
a. Conditions that mean you should not use oral contra-
ceptives-
Clots in the legs or lungs.
Clots in the legs or lungs in the past.
A stroke, heart attack, or angina pectons.
Known or suspected cancer of the breast or sex organs.
Unusual vaginal bleeding that has not yet been diagnosed.
Known or suspected pregnancy.
b. Conditions that your doctor will want to watch dosely or
which might cause him to suggest another method of con-
traception.
A family history of breast cancer.
Breast nodules, fibrocystic disease of the breast, oranabnormal
mammogram.
Diabetes. Heart or kidney disease.
High blood pressure. Epilepsy.
High cholesterol. Mental depression.
Cigarette smoking. Fibroid tumors of the uterus.
Migraine headaches. Gallbladder disease.
c. Once you are using oral contraceptives, you should be alert
for signs of a serious adverse effect and call your doctor if they
occur:
Sharp pain in the chest, coughing blood, or sudden shortness
of breath (indicating possible clots in the lungs).
Pain in the calf (possible clot in the leg).
Crushing chest pain or heaviness (indicating possible heart
attack).
Sudden severe headache or vomiting, dizziness or fainting,
disturbance of vision or speech orweakness or numbness in an
arm or leg (indicating a possible stroke).
Sudden partial or complete loss of vision (indicating a possible
clot in the eye).
Breast lumps (you should ask your doctor to show you how to
examine your own breasts).
Severe pain in the abdomen (indicating a possible ruptured
tumor of the liver).
Severe depression.
Yellowing of the skin (jaundice).
2. How to Take the Pill So That it is Most Effective.
To achieve maximum contraceptive effectiveness, ORTHO-
NOVUM, MODICON and MICRONOR must be taken exactly as
directed and at intervals not exceeding 24 hours.
21-Day Regimen: Counting the first day of menstrual flow as
"Day 1," take one tablet daily from the 5th through the 25th day
of the menstrual cycle. If the first tablet is taken later than the 5th
day of the menstrual cycle or postpartum, contraceptive
reliance should not be placed on ORTHO-NOVUM or
MODICON until after the first seven consecutive days of ad-
ministration. Take a tablet the same time each day, preferably at
bedtime, for 21 days, then wait for7 days during which time a
menstrual period usually occurs. Following this 7-day waiting
period, start taking a tablet each day for the next 21 days, thus
using a three-weeks-on, one-week-off dosage regimen.
28-Day Regimen: The first white or yellow tablet should be
taken on the first Sunday after the menstrual period begins. If
period begins on Sunday, begin taking tablets that day. Take
one white or yellow tablet at the same time each day for 21 con-
secutive days, then take one green tablet daily for 7 days during
which time your menstrual period usually occurs. During the
FIRST cycle, it is important that you use another method of
birth control until you have taken a white or yellow tablet daily
for seven consecutive days. After 28 tablets have been taken,
(last green tablet will always be taken on a Saturday) take the
first tablet (white or yellow) from your next package the follow-
ing day (Sunday) whether or not you are still menstruating.
With the 28-day regimen, pills are taken every day of the year.
20-Day Regimen: In the initial cycle, the dosage of ORTHO-
NOVUM 10 mg for contraception is one tablet administered
daily from the 5th through the 24th day of the menstrual cycle,
counting the first day of the menstrual flow as "Day 1." If
ORTHO-NOVUM 10mg is first taken later than the fifth day of
the first menstrual cycle of medication or postpartum, con-
traceptive reliance should not be placed on ORTHO-
NOVUM 10 mg until after the first seven consecutive days of
administration. In all subsequent cycles the first tablet is
taken on the 7th day following completion of the previous
20-day course, i.e., 6 days without medication.
In the treatment of hypermenorrhea and endometriosis, your
physician will discuss the regimen with you.
Continuous Regimen (MICRONOR): The first MICRONOR
Tablet should be taken on the first day of the menstrual penod.
Take one tablet at the same time each day without interruption
for as long as contraceptive protection is desired.
The effectiveness of progestogen-only oral contraceptives,
such as MICRONOR, is lower than that of the combination oral
contraceptives containing both estrogen and progestogen. If
100 women utilized an estrogen-containing oral contraceptive
for a period of one year, generally less than one pregnancy
would be expected to occur; however, if MICRONOR had been
utilized, approximately three pregnancies might occur.
Women who participated in the clinical studies with
MICRONOR and who had not taken other oral contraceptives
before starting MICRONOR had a higher pregnancy rate (four
women out-of 100), particularly during the first six months of
therapy, and to a large extent because they did not take their
tablets correctly.
Of course, if you don't take your tablets as directed, or forget to
take them every day, the chance you may become pregnant is
naturally greater.
MICRONOR (norethindrone) vill probably cause some changes
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in your menstrual pattern. Your cycle, that is the time between
menstrual periods, will vary. For example, you might have a
28-day cycle, followed by a 17-day cycle, followed by a 35-day
cycle, etc. This is common with MICRONOR.
While using MICRONOR, your period may be longer or shorter
than before. If bleeding lasts more than eight days, be sure to let
your doctor know
Occasionally women who are not taking the pill miss a period. This
is also true for women taking the pill and it has been reported to
occur as frequently as several times each year in some women,
depending on various factors, such as age and prior history,
Therefore, if you missa period, or if you are taking mini-pills and it is
45 days or more from the start of your last menstrual period you
may be pregnant and you should consult your physician before
continuing to take the pill. (Your doctor is the best source of infor-
mation about this.) The pill should not be used when you are preg-
nant because of some reports of the possibility of adverse effects
on the developing child. Very rarely, women who are using the pill
as directed becomepregnant. The likelihood of becoming pregnant
if you occasionally miss one or two pills is naturally higher. If you
miss a period, especially if you have not taken the pll regularly, you
should use an alternative method of contraception until pregnancy
has been ruled out. If you have missed more than one tablet at any
time, you should immediately start using an additional method of
contraception and complete your pill cycle.
3. Periodic Examination.
Your doctor will take a complete medical and family history before
prescribing oral contraceptives. At that time and about once a year
thereafter, he will generally examine your blood pressure, breasts,
abdomen, and pelvic organs (including a Papanicolaou smear, i.e.,
test for cancer).
Summary
Oral contraceptives are the most effective method, except steriliza-
tion, for preventing pregnancy. Other methods, when used consci-
V JO UIRNAL [Vol. 14:590
entiously, are also very effective and have fev-,er risks
Women who use oral contraceptives should not smoke
In addition, if you have certain conditions or have had th; condj
tions in the past, you should not use oral contraceptives bcc.ju-.c
theriskistoogreat These conditionsare listed in the booklet Ifyou
do not have these conditions and decide to use the "pill," plea, v
read the booklet carefully so that you can use the "pill "
Based on his or her assessment of your medical needs, your durtorhas prescribed this drug for you Do not give thu drug to anyone
else.
ORTHO PHARMA('EL'ICAL (OI'POtHA I10N
Rarlan, New Jersey 088w),
ORTHO PHARMACEUii,AL., IN(
Dorado, Puerto Rico 0o646,
APPENDIX C
The Physician Package Insert
P-63110-000-4 ORTHO-NOVUM Tablets
and MODICON Tablets
MICRONOR
DESCRIPTION
ORTHO-NOVUM 1150021 Tablets are a combination oral contraceptive.Each ORTHO-NOVUM 1150021 Tablet contains 1 mg of the progesta-
tlonat compound, norethindrone (17-hydroxy-19-noro17apregn4.en20-yn.
3-one), together with 0.05 mg of the estrogenic compound, mestranol(3-methoxy-19-nor-17a-pregna-1,3,5 (10)-trlen-20-yn-17-ol).
ORTHO-NOVUM 11500 28 Tablets are a combination oral contraceptive.Each yellow ORTHO-NOVUM 1150028 Tablet contains 1 mg of the pro-gestational compound, norethindrone (17-hydroxy-19-nor-17u-pregn4en
20-yn-3-one). together with 0.05 mg of the estrogenic compound,
mestranot (3-mathoxy-19-nor-17a*pregna-1.,3,5 (10)-trlen-20-yn-17-ol). Eachgreen tablet contains inert ingredients.
ORTHO-NOVUM 1180 0 21 Tablets are a combination oral contraceptive.Each ORTHO-NOVUM 11800 21 Tablet contains 1 mg of the progesta.tional compound, norethindrone (17-hydroxy-19-nor-17upregn-4-e-20.yn.
3-one), together with 0.08 mg of the estrogenic compound, mestrano(3-methoxy-19-nor-17a-pregna-1,3,5 (10)-trlen-20-yn-17-ol).
ORTHO-NOVUM 11800 28 Tablets are a combination oral contraceptive.Each white ORTHO-NOVUM 1180028 Tablet contains 1 mg of the pro-gestational compound, norethindrone (17-hydroxy-19-nor-17,:pregn4-en
20-yn-3-one). together with 0.08 mg of the estrogenic compound,
mestranol (3-methoxy-19-nor-17wpregna-1,3,5 (t10trien-20-yn-17-ol). Eachgreen tablet contains inert ingredients.
ORTHO-NOVUP.M 2 mg 0 21 Tablets are a combination oral contraceptive.Each ORTHO-NOVUM 2 mg 0 21 Tablet contains 2 mg of the progesta-tlional compound, norethlndrone (17-hydroxy-19-nor-17-pregn-4en.20-yn
3-one), together with 0.10 mg of the estrogenic compound, mestranol(3-methoxy-19-nor-17apregna1,3,5 (10l-trlen-20.yn-17-ol).
ORTHO-NOVUM 10 mg Tablets are a combination oral contraceptive
Each ORTHO-NOVUM 10 mg Tablet contains 10 mg of the progostatlonal
compound, norethindrone (17hydroxy-19nor-17a.pregn4 
-n.20.yn3.ne),together with 0.06 mg of the estrogenic compound, mostranol(3-methoxy.19-nor.17upiegna-1,35 (10-trien.20-yn17oil
OL OH
ncieihindrcr e Crrjar:,
MODICON Tablets are a combination oral contraceptive Each MODICONTablet contains 05 mg of the progestational compound, norethindionn(17-hydroxy-19-nor-17prcgn4en.20.yn3-one)0 together with 0035 mg ofthe estrogenic compound, elhlnyl ostradlol (19-nor.17a-ptegna.1,3,5(1)-t nenm20-yne-3,17.dlQ.
MODICON 28 Tablets are a combination oral contraceptive Each whiteMODICON 28 Tablet contains 05 mg of the progestatlonal compound,
norethindrone 17hydroxy.19-nor,17.prgn-4.en2.yn.3
0 neL togetherwith 0.035 mg of the estrogenic compound, elhinyl ootadlol (1a-nor,1ta-pregna-1,3,5 (10}-trien-20-yne-3,17.dil). Each green tablet contains InertIngredients.
OH
CHI
norelhindrone
0,Cp ron
CHItOH-- 2C8
1. II ethinyt estradlal
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PHAMA CIST LIABILITY
MICRONOR Tablets are a progestogen-only oral contraceptive. Each
MICRONOR tablet contains 0.35 mg of the purified crystalline compound,
norethindrone (17-hydroxy-19-nor-17a-pregn-4-en-20-yn-3-one). a synthetic
progestogen
OH
CH, 
-C C H
CLINICAL PHARMACOLOGY FOR
COMBINATION ORAL CONTRACEPTIVES ONLY
Combination oral contraceptives act primarily through the mechanism of
gonadolropln suppression due to the estrogenic and progestational
acltiviy of the ingredients. Although the primary mechanism of action Is
Inhibilton of ovulation, alterations In the genital tract including changes
In the cervical mucus (which Increase the difficulty of sperm penetration)
and the endometrium (which reduce the likelihood of implantation) may
also contribute to contraceptive effectiveness.
CLINICAL PHARMACOLOGY
PROGESTOGEN ORAL CONTRACEPTIVES
The primary mechanism through which MICRONOR prevents conception
Is not known, but progestogen-only contraceptives are known to alter the
cervical mucus, exert a progestational effect on the endometrium, inter-
fering with Implantation, and, in some patients, suppress ovulation.
INDICATIONS AND USAGE
ORTHO-NOVUM 1150021. ORTHO-NOVUlM 1150028 ORTHO-NOVUM
1180,E21. ORTHO-NOVUM 1180028, MODICON, MODICON 28 and
MICRONOR are indicated for the prevention of pregnancy in women who
elect to use oral contraceptives as a method of contraception.
ORTHO-NOVUM 2 mg 0 21 is Indicated for the treatment of hypermenor-
rhea ORTHO-NOVUM 2 mg 021 is Indicated for the prevention of
pregnancy in women who elect to use oral contraceptives as a method of
contraception (See first paragraph immediately following the opening
WARNINGS statement.)
ORTHO-NOVUM 10 mg Is Indicated for the treatment of endometriosis
and hypermenorrhea. ORTHO-NOVUM 10 mg is indicated for the preven-
tion of pregnancy In women who elect to use oral contraceptives as a
method of contraception. (See second paragraph Immediately following
the opening WARNINGS statement.)
Oral contraceptives are highly ellective. The pregnancy rate in women
using conventional combination oral contraceptives (containing 35 mcg
or more of ethinyl estradiol or 50 mcg or more of mestranol) is generally
reported as less than one pregnancy per 100 woman-years of use. Slightly
higher rates (somewhat more than one pregnancy per 100 woman-years
of use) are reported for some combination products containing 35 mcg or
less of ethinyl estradiol, and rates on the order of three pregnancies per
100 woman-years are reported for the progestogen-only oral contracep-
tliver.
Those rates are derived from separate studies conducted by different in-
vestigalors In several population groups and cannot be compared
precisely. Furthermore, pregnancy rates tend to be lower as clinical
studies are continued, possibly due to selective retention in the longer
studies of those patients who accept the treatment regimen and do not
discontinue as a result of adverse reactions, pregnancy or other reasons.
In clinical trials with ORTHO-NOVUM 11500 21,3.852 patients completed
45.937 cycles, and a total of 10 pregnancies was reported. This represents
a pregnancy rate of 0.26 per 100 woman-years.
In clinical trials with ORTHO-NOVUM 11500 28,1,590 patients completed
7,330 cycles, and a total of three pregnancies was reported. This repre-
cents a pregnancy rate of 0.5 per 100 woman-years.
In clinical trials with ORTHO-NOVUM 1180021. and ORTHO-NOVUM
1180028. 3.464 patients completed 34.068 cycles, and a total of five
pregnancies was reported. This represents a pregnancy rate of 0.18 per
100 woman-years.
In clinical trials with ORTHO-NOVUM 2 mg 020, 6,097 patients com-
pleted 121,233 cycles, and a total of 13 pregnancies was reported. This
represents a pregnancy rate of 0.13 per 100 woman-years. In clinical trials
wilh ORTHO-NOVUM 2 mgO21, 965 patients completed 3,743 cycles.
and no pregnancies were reported. This represents a pregnancy rate of
00 per 100 woman-years.
In clinical trials with ORTHO-NOVUM 10 mg. 1,185 patients completed
32,906 cycles, and a total of one pregnancy was reported. This represents
a pregnancy rate of 0.03 per 100 woman-years.
The dropout rate for medical reasons, as observed in the clinical trials
conducted with MODICON. appears to be somewhat higher than ob-
served with higher dose combination products. The dropout rate due to
menstrual disorders and Irregularities was also somewhat higher,
dropouts being equally split between menstrual disorders and irregular-
Ities and other medical reasons attributable to the drug.
In clinical trials with MODICON and MODICON 28, 1,103 patients com-
pleted 12,948 cycles of use, and a total of four pregnancies was reported.
This represents a pregnancy rate of 0.37 per 100 woman-years.
In clinical trials with MICRONOR, 2,963 patients completed 25,901 cycles
of therapy, end a total of 55 pregnancies was reported. This represents an
average pregnancy rate of 2.54 per 100 woman-years.
A higher pregnancy rate of 3.72 was recorded in "fresh" patients (those
who had never taken oral contraceptives prior to starting MICRONOR
therapy) to a large extent because of incorrect tablet intake. This corn-
pares to the lower pregnancy rate of 1.95 recorded in "changeover"
patients (those switched from other oral contraceptives).
This difference was found to be statistically significant. Furthermore, an
even greater statistically significant difference in pregnancy rates be-
tween these two groups was found during the first six months of
MICRONOR therapy. Therefore, It Is especially Important for "fresh"
patients to strictly adhere to the regimen.
Table 1 gives ranges of pregnancy rates reported in the literature' for
other means of contraception. The efficacy of these meds of contracep-
tlon (except the IUD) depends upon the degree of adherence to the
method.
Table 1
Pregnancies Per 100 Women-Years
IUD. less than 1-6;
Diaphragm with spermicidal product (creams or jellies), 2-20;
Condom, 3-36; Aerosol foams. 2-29; Jellies and creams, 4-36;
Periodic abstinence (rhythm) all types, less than 1-47;
1. Calendar method. 14-47;
2. Temperature method, 1-20;
3.Temperature method-intercourse only in postovulatory phase.
less than 1-7;
4. Mucus method, 1.25;
No contraception. 60-80.
DOSE-RELATED RISK OF THROMBOEMBOLISM
FROM ORAL CONTRACEPTIVES
Two studies have shown a positive association between the dose of
estrogens In oral contraceptives and the risk of thromboembolism."- For
this reason. It Is prudent and in keeping with good principles of therapeu-
tics to minimize exposure to estrogen. The oral contraceptive product
prescribed for any given patient should be that product which contains
the least amount of estrogen that Is compatible with an acceptable
pregnancy rate and patient acceptance. It Is recommended that new ac-
ceptors of oral contraceptives be started on preparations containing
.05 mg or less of estrogen.
CONTRAINDICATIONS
Oral contraceptives should not be used In women with any of the follow-
Ing conditions:
1. Thrombophlebltis or thromboembelic disorders.
2. A past history of deep vein thrombephleblils or thromboembolic
disorders.
3. Cerebral vascular or coronary artery disease.
4. Known or suspected carcinoma of the breast.
5. Known or suspected estrogen-dependent neoplasla.
6. Undiagnosed, abnormal genital bleeding.
7. Known or suspected pregnancy (see WARNINGS, No. 5).
WARNINGS
Cigarette smoking Increases the risk of serious cardiovascular side
effects from oral contraceptive use. This risk Increases with age and
with heavy smoking (15 or more cigarettes per day) and Is quite
marked In women over 35 years of age. Women who use oral con-
traceptives should be strongly advised not to smoke.
The use of oral contraceptives Is associated with Increased risk of
several serious conditions Including thromboembollsm, stroke,
myocardial Infarction, hepatic adenoma, gallbladder disease,
hypertension. Practltloners prescribing oral contraceptives should
be familiar with the following Information relating to these risks.
ORTHO-NOVUM 2 mgO 21 should only be used for contraception when
lower dose formulations prove unacceptable.
ORTHO-NOVUM 10mg should be used for contraception only when for-
mulations with lower progestogen doses prove unacceptable.
1.THROMBOEMBOLIC DISORDERS AND OTHER VASCULAR PROB-
LEMS. An increased risk of thromboembolic and thrombotic disease
associated with the use of oral contraceptives is well established. Four
principal studies in Great Britain' I- and three In the United States'"
have demonstrated an increased risk of fatal and nonfatal venous throm-
boembelism and stroke, both hemorrhagic and thrombotic. These
studies estimate that users of oral contraceptives are 4 to 11 times more
likely than nonusers to develop these diseases without evident cause
(Tables 2, 4). Overall excess mortality due to pulmonary embolism or
stroke Is on the order of 1.0 to 3.5 deaths annually per 100.000 users and
Increases with age (Table 3).
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Table 2
Hospitalization Rates Due to Venous Thromboembolic Disease'
Admissions annually per 100,000 women, age 20-44
Users of oral contraceptives ................................... 45
Nonusers .................................................. 5
Table 3
Death Rates Due to Pulmonary Embolism or Cerebral Thrombosis'
-Deaths Annually Per 100,000 Nonpregnant Women
Age2Oto34 Age35to44
Users of oral contraceptives ........... _ 1.5 3.9
Nonusers ........................... .2 .5
CEREBROVASCULAR DISORDERS
In a collaborative American study''0 of cerebrovascular disorders In
women with and without predisposing causes, it was estimated that the
risk of hemorrhagic stroke was 2.0 times greater In users than in
nonusers and the risk of thrombotic stroke was 4.0 to 9.5 times greater in
users than in nonusers (Table 4).
Table 4
Summary of Relative Risk of Thromboembollc Disorders
and Other Vascular Problems In Oral Contraceptive Users
Compared to Nonusers
Relative risk, times greater
Idiopathic thromboembolic disease ....................... 4.11
Post surgery thromboembolic complications ................... 4-6
Thrombotic stroke ........ ....................... 4-9.5
Hemorrhagic stroke ...................................... 2
Myocardial infarction ............... ............... 2-12
MYOCARDIAL INFARCTION
An Increased risk of myocardial infarction associated with the use of oral
contraceptives has been reported'" ' confirming a previously
suspected association (Tables 5 & 6). These studies, conducted in the
United Kingdom, found, as expected, that the greater the number of
underlying risk factors for coronary artery disease (cigarette smoking,
hypertension, hypercholesterolemia, obesity, diabetes, history of
preeclamptic toxemia), the higher the risk of developing myocardial in-
farction, regardless of whether the patient was an oral contraceptive user
or not. Oral contraceptives, however, were found to be a clear additional
risk factor.
The annual excess case rate (increased risk) of myocardial Infarction
(fatal and nonfatal) In oral contraceptive users was estimated to be ap
proximately 7 cases per 100,000 women users In the 30-39 age group and
67 cases per 100,000 women users In the 40-44 age group.
In terms of relative risk, it has been estimated-- that oral contraceptive
users who do not smoke (smoking is considered a major predisposing
condition to myocardial infarction) are about twice as likely to have a
fatal myocardial infarction as nonusers who do not smoke. Oral con-
traceptive users who are also smokers have about a 5-fold Increased risk
of fatal infarction compared to users who do not smoke, but about a 10-to
12-fold increased risk compared to nonusers who do not smoke. Further-
more, the amount of smoking is also an important factor. In determining
the Importance of these relative risks, however, the baseline rates for
various age groups, as shown in Table 5, must be given serious con.
sideration. The importance of other predisposing conditions mentioned
above in determining relative and absolute risks has not as yet been
quantified; ills quite likely that the same synergistic action exists, but
perhaps to a lesser extent.
Table 5
Estimated Annual Mortality Rate Per 100.000 Women
From Myocardial Infarction By Use Of
Oral Contraceptives, Smoking Habits, And Age (in years)
Myocardial Infarction
Women aged Women aged
30-39 40-44
Non- Non-
Smoking habits Users users Users users
All smokers ............. 10.2 2.6 62.0 15.9
Heavy'-- --.............. 13.0 5.1 78.7 31.3
Light . ................ 4.7 .9 28.6 5.7
Nonsmokers .............. 1.8 1.2 10.7 7.4
Smokers and
nonsmokers ............ 5.4 1.9 32.8 11.7
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Table 6
Myocardial Infarcteon Rates In Users And Nonusors Of
Oral Contraceptives In Britain" ,1 1'- Cases Annually
Per 100,000 Women
Nonfatal Fatal
Age Ago Ago Ago
30to39 401o44 30to39 40to44
Users of oral
contraceptives ......... 5.6 50.9
Nonusers of oral
contraceptives ......... 2.1 9.9
Relative risk .............. 2.7 5.7
5.4 32.0
1.9 12.0
2.8 28
Risk of Dose
In an analysis of data derived from several national adverse reaction
reporting systems' , British Investigators concluded that the risk of throm,
boembolism Including coronary thrombosis Is direclly related to the do
of estrogen used In oral contraceptive preparations containing 100 meg
or more of estrogen were associated with a higher risk of thrombaom
bolism than those containing 50-80 mcg Ol estrogen Their analysis did
suggest, however, that the quantity of estrogen may not be the solo fa,
for involved. This finding has been confirmed In the United States.
Careful epldemlologlcal studies to determine the degree of thromboem
bolic risk associated with progestogen-only oral contracepllves have not
been performed. Cases of thromboemboloc disease have been reported In
women using these products, and they should not be presumed to be lies
of excess risk.
The risk of thromboembolic and thromboll disorders, In both users and
nonusers of oral contraceptives, Increases with ago. Oral conltracepllves
are, however, an independent risk factor for these events,
ESTIMATE OF EXCESS MORTALITY FROM
CIRCULATORY DISEASES
A large prospective study" carried out in the United Kingdom estimated
the mortality rate per 100,000 women per year from diseases ol the cr-
culatory system for users and nonusers of oral contraceptives accotding
to age, smoking habits, and duration of use. The overall oxcess death rate
annually from circulatory diseases for oral contracepllve users was
estimated to be 20 per 100.000 (ages 15-34-5100.000; ages
3544-33100.0; ages 45-49-1401100,000), the risk being concentrated
In older women, In those with a long duration of use, and In cigarette
smokers. It was not possible, however, to examine the Interrelationships
of age, smoking, and duration of use, nor to compare the elcts ol con.
tinuous versus Intermittent use. Although the study showed a 10-fold In-
crease In death due to circulatory diseases In users for live or more years,
all of these deaths occurred In women 35 or older Until larger numbers ol
women under 35 with continuous use for live or more years are available,
It Is not possible to assess the magnitude of the relative risk for this
younger age group.
This study reports that the Increased risk of circulatory diseases may per,
sist after the pill Is discontinued.
Another study published at the same time confirms a previously reported
Increase of mortality In pill users from cardiovascular disease,"
The available data from a variety of sources have been analyzed" to
estimate the risk of death associated with various methods of contracep-
tion. The estimates of risk of death for each moothd Include the com-
bined risk of the contraceptive method (e.g., thromboembotlo and throm-
botic disease In the case of oral contraceptives) plus the risk atlidbulablo
to pregnancy or abortion in the event of method failure. This latter risk
varies with the effectiveness of the contraceptive method The lindings of
this analysis are shown In Figure I below." The study concluded that the
mortality associated with all methods of birth control Is low end below
that associated with childbirth, with the exception al oral contraceptives
In women over 40 who smoke. (The rates given for pill onlylamokos for
each age group are for smokers as a class. For "heavy" smokers [Mote
than 15 cigarettes a day), the rates given would be about double; lor
'light" smokers [less than 15 cigarettes a day], about 50 percent.)
The mortality associated with oral contracepllve use In nonsmokers over
40 Is higher than with any other method of contraception In that ago
group.
The lowest mortality Is associated with the condom or diaphragm backed
up by early abortion.
The risk of thromboembolic and thrombolc disease associated with oral
contraceptives Increases with ago after approximately ego 30 and, for
myocardial Infarction, Is further Increased by hyoertenslon, hyper-
cholesterolemla, obesity, diabetes, or history of prOcclamptlc toxemia
and especially by cigarette smoking, The risk of myocardial infarction In
oral contraceptive users Is substantially Increased In women ago 40 and
over, especially those with other risk factors The use of oral conlracep.
lives In women In this age group Is not recommended
Based on the data currently available, the following chart gives a gross
estimate of the risk of death from circulatory disordes associated with
the use of oral contraceptives:
'Heavy smoker 15 or more cigarettes per day. From Jain, A.K., Studies in
Family Planning, 8:50,1977.
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SMOKING HABITS AND OTHER PREDISPOSING CONDITIONS-
RISK ASSOCIATED WITH USE OF ORAL CONTRACEPTIVES
Below
Age 30 30-39 40+
Heavy smokers ...................... C B A
Light smokers ........................ D C BNonsmokers (no predisposing conditions) . D C,D C
Nonsmokers (other predisposing
conditions) ....................... C C,B B,A
A-Use associated with very high risk.
B-Use associated with high risk.
C-Use associated with moderate risk.
D-U e associaled with low risk.
The physician and the patient should be alert to the earliest manifesta.
lions of thromboemboll and thrombotic diso:gera (e.g., throm-
bophlebitis, pulmonary embolism, cerebrovascular Insufficiency, cor-
onary occlusion, retinal thrombosis, and mesenteric thrombosis). Should
any of these occur or be suspected, the drug should be discontinued
Immediately.
A four. to six-fold Increased risk of post surgery thromboembolic com-
plications has been reported in oral contraceptive use's." 11 If feasible,
oral contraceptives should be discontinued at least four weeks before
surgery of a type associated with an increased risk of thromboembollsm
or prolonged Immobilization.
2 OCULAR LESIONS. There have been reports of neuro-ocular lesions
such as optic neuritis or retinal thrombosis associated with the use of
oral contraceptives. Discontinue oral contraceptive medication If there is
unexplained, sudden or gradual, partial or complete loss of vision; onset
of proptosis or diplopia; papilledema; or retinal vascular lesions and In-
stitute appropriate diagnostic and therapeutic measures.
3. CARCINOMA. Long-term continuous administration of either natural or
synthetic estrogen in certain animal species increases the frequency of
carcinoma of the breast. cervix, vagina, and liver. Certain synthetic pro-
gestogens, none currently contained In oral contraceptives. have been
noted to Increase the incidence of mammary nodules, benign and malig-
nant, In dogs.
In humans, three case control studies have reported an lrcreased risk of
endometrial carcinoma associated with the prolonged use of exogenous
estrogen In postmenopausal women." -"" One publication- reported on
the first 21 cases submitted by physicians to a registry of cases of
d.donocarcinoma of the endometrium in women under 40 on oral con-
Iraceptives. Of the cases found in women without predisposing risk fa-
tors for adenocarcinoma of the endometrium (e.g., irregular bleeding at
the time oral contraceptives were first given, polycystic ovaries), nearly
all occurred In women who had used a sequential oral contraceptive.
Those products are no longer marketed. No evidence has been reported
suggesting an increased risk of endometrial cancer in users of conven-
tional combination or progestogee-only oral contraceptives.
Several studies ' "" have found no Increases in breast cancer in women
taking oral contraceptives or estrogens. One study", however, while also
noting no overall increased risk of breast cancer in women treated with
oral contraceptives, found an excess risk in the subgroups of oral con-
traceptive users with documented benign breast disease. A reduced
occurrence of benign breast tumors in users of oral contraceptives has
b en weldocumented..'" """
In summary. there is at present no confirmed evidence from human
studies of an increased risk of cancer associated with oral contracep-
tives Close clinical surveillance of all women taking oral contraceptives
is. nevertheless, essential. In all cases of undiagnosed persistent or
recurrent abnormal vaginal bleeding, appropriate diagnostic measures
should be taken to rule out malignancy. Women with a strong family
history of breast cancer or who have breast nodules, fibrocystic disease
or abnormal mammograms should be monitored with particular care if
they elect to use oral contraceptives instead of other methods of con-
traception.
Figure 1. Estimated annual number of deaths associated with control of
fertility and no control per 100.000 nonsterile women, by regimen of
control and age of woman.
Annual deaths
Regimen of control
o No method 0 Abortion only 0 Pill only/nonsmokers
0 Pill only/ [3 IUDOs only 0 Traditional contraception only
smokers (Diaphragm or condom)
I Traditional contraception and abortion
4. HEPATIC TUMORS. Benign hepatic adenomas have been found to be
associated with the use of oral contraceptives."""... One study"
showed that oral contraceptive formulations with high hormonal potency
were associated with a higher risk than lower potency formulations.
Although benign, hepatic adenomas may rupture and may cause death
through Intra-abdominal hemorrhage. This has been reported in short-
term as well as long-term users of oral contraceptives. Two studies relate
risk with duration of use of the contraceptive, the risk being much greater
alter four or more years of oral contraceptive use."" While hepatic
adenoma is a rare lesion, It should be considered in women presenting
abdominal pain and tenderness, abdominal mass or shock.
A few cases of hepatocellular carcinoma have been reported in women
taking oral contraceptives. The relationship of these drugs to this type of
malignancy is not known at this time.
5. USE IN OR IMMEDIATELY PRECEDING PREGNANCY, BIRTH
DEFECTS IN OFFSPRING, AND MALIGNANCY IN FEMALE OFFSPRING.
The use of female sex hormones-both estrogenic and progestational
agents-during early pregnancy may seriously damage the offspring. It
has been shown that females exposed in utero to diethylstilbestrol, a
nonsteroidal estrogen, have an increased risk of developing in later life a
form of vaginal or cervical cancer that is ordinarily extremely rare." "
This risk has been estimated to be of the order of 1 to 4 in 1000 expo-
sures." "Although there Is no evidence at the present time that oral con-
traceptives further enhance the risk of developing this type of malig-
nancy, such patients should be monitored with particular care if they
elect to use oral contraceptives Instead of other methods of contracep-
tion. Furthermore, a high percentage of such exposed women (from 30 to
90%) have been found to have epithelial changes of the vagina and
cervix."" .== Although these changes are histologically benign, it is not
known whether this condition Is a precursor of vaginal malignancy. Male
children so exposed may develop abnormalities of the urogenital
tract. - " Although similar data are not available with the use of other
estrogens, It cannot be presumed that they would not induce similar
changes.
An increased risk of congenital anomalies, Including heart defects and
limb defects, has been reported with the use of sex hormones, including
oral contraceptives, in pregnancy.-' One case control study" has
estimated a 4.7-fold Increase in risk of limb-reduction defects In Infants
exposed in utero to sex hormones (oral contraceptives, hormonal
withdrawal tests for pregnancy or attempted treatment for threatened
abortion). Some of these exposures were very short and involved only a
few days of treatment. The data suggest that the risk of limb-reduction
1979]
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defects in exposed fetuses is somewhat less than one in 1,000 live births.
In the past, female sex hormones have been used during pregnancy in an
attempt to treat threatened or habitual abortion. There is considerable
evidence that estrogens are Ineffective for these indications, and there Is
no evidence from well-controlled studies that prgestogens are effective
for these uses.
There Is some evidence that triploldy and possibly other types of
polyploldy are increased among abortuses from women who become
pregnant soon after ceasing oral contraceptives. " Embryos with these
anomalies are virtually always aborted spontaneously. Whether there Is
an overall increase in spontaneous abortion of pregnancies conceived
soon after stopping oral contraceptives is unknown. Pregnancy should
be ruled out before Initiating or continuing the contraceptive regimen.
Pregnancy should always be considered if withdrawal bleeding does not
occur. If pregnancy Is confirmed, the patient should be apprised of the
potential risks to the fetus and the advisability of continuation of the
pregnancy should be discussed In the light of these risks.
(See indications for use of ORTHO-NOVUM 10mg in the treatment of
endometriosis.)
It Is also recommended that women who discontinue oral contraceptives
with the Intent of becoming pregnant use an alternate form of contracep.
tion for a period of time before attempting to conceive. Many clinicians
recommend three months although no precise Information Is available on
which to base this recommendation.
The administration of progestogen-only or progestogenestrogen cow-
binations to Induce withdrawal bleeding should not be used as a test of
pregnancy.
6. GALLBLADDER DISEASE. Studies" -i , report an Increased risk of
surgically confirmed gallbladder disease In users of oral contraceptives
and estrogens. In one study, an Increased risk appeared after two years
of use and doubled after four or five years of use. In one of the other
studies, an Increased risk was apparent between sIx and twelve months
of use.
7. CARBOHYDRATE AND UPID METABOLIC EFFECTS. A decrease In
glucose tolerance has been observed In a significant percentage of
patlents on oral contraceptives. For this reason, predlabelc and diabetic
patients should be carefully observed while receiving oral contraceptives.
An Increase In triglycerides and total phosphollpids has been observed In
patients receiving oral contraceptives."
8. ELEVATED BLOOD PRESSURE. An Increase In blood pressure has
been reported In patients receiving oral contraceptives.,' In some women
hypertension may occur within a few months of beginning oral con-
traceptive use. In the first year of use, the prevalence of women with
hypertension is low in users and may be no higher than that of a cor.
parable group of nonusers. The prevalence In users Increases, however,
with longer exposure, and In the fifth year of use Is two and a half to three
times the reported prevalence In the first year. Age Is also strongly cor.
related with thu development of hypertension in oral contraceptive users.
Women who previously have had hypertension during pregnancy may be
more likely to develop elevation of blood pressure when given oral con-
traceptives. Hypertension that develops as a result of taking oral con.
traceptives usually returns to normal after discontinuing the drug.
9. HEADACHE. The onset or exacerbation of migraine or development of
headache of a new pattern which is recurrent, persistent, or severe, re-quires discontinuation of oral contraceptives and evaluation of the
cause.
10. BLEEDING IRREGULARITIES. Breakthrough bleeding, spotting, and
amenorrhea are frequent reasons for patients discontinuing oral con-
traceptives. In breakthrough bleeding, as In all cases of Irregular bleedingfrom the vagina, nonfunctional causes should be borne in mind. In un-
diagnosed persistent or recurrent abnormal bleeding from the vagina,
adequate diagnostic measures are indicated to rule out pregnancy or
malignancy. If pathology has been excluded, time or a change to another
formulation may solve the problem. Changing to an oral contraceptive
with a higher estrogen content, while potentially useful in minimizing
menstrual irregularity, should be done only If necessary since this may
increase the risk of thromboembolic disease.
An alteration in menstrual patterns is likely to occur In women using
progestogen-only oral contraceptives. The amount and duration of flow,
cycle length, breakthrough bleeding, spotting and amenorrhea will prob-
ably be quite variable. Bleeding Irregularities occur more frequently with
the use of progestogen-only oral contraceptives than with the combina-
tions and the dropout rate due to such conditions Is higher.
Women with a past history of oigomenorrhea or secondary amenorrhea
or young women without regular cycles may have a tendency to remain
anovulatory or to become amenorrheic after discontinuation of oral con-
traceptives. Women with these preexisting problems should be advised
of this possibility and encouraged to use other contraceptive methods.
Postuse anovulatron, possibly prolonged, may also occur in women
without previous irregularities.
11. ECTOPIC PREGNANCY. Ectopic as well as intrauterine pregnancy
may occur in contraceptive failures. However, in progestogen-only oral
contraceptive failures, the ratio of ectopic to Intrauterine pregnancies is
higher than in women who are not receiving oral contraceptives, since
the drugs are more effective in preventing intrauterine than ectopic
pregnancies.
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12. BREAST FEEDING. Oral contraceptives given In the postpartum
period may Interfere with lactation. There may boa decrease In the quaon
tity and quality of the breast milk. Furthermore. a small fraction of thehormonal agents in oral contraceptives has ben Identilied In the milk of
mothers receiving these drugs." The etfects, If any on the breast-fed
child have not been determined. If leasible, the use of oral contracepflvo
should be deferred until the infant has ben weaned,
PRECAUTIONS
General
1. A complete medical and family history should be taken prior to the
initiation of oral contraceptives. The pretreatment and periodic physical
examinations should include special reference to blood prossuro,
breasts, abdomen and pelvic organs, Including Papanlcolaou smear and
relevant laboratory tests. As a general rule, oral contraceptives should
not be prescribed for longer than one year without another physical ox.
amination being performed.
2. Under the influence of estrogen-progestogen preparatlons, pro.
existing uterine Ieiomyomata may increase in size.
3. Patients with a history of psychic depression should be carefully
observed and the drug discontinued if depression recurs to a sarious
degree. Patients becoming significantly depressed while taking oral con,
traceptives should stop the medication and use an alternato method of
contraception In an attempt to determine whether the symptom Is
drug-related.
4. Oral contraceptives may cause some degree of fluid retention. They
should be prescribed with caution, and only with careful monitoring, In
patients with conditions which might be aggravated by fluid retention,
such as convulsive disorders, migraine syndrome, asthma, or cardiac or
renal insufficiency.
S. Patients with a past history of jaundice during pregnancy have an In,
creased risk of recurrence of jaundice while receiving oral contraceptive
therapy. If jaundice develops in any patient receiving such drugs, the
medication should be discontinued,
6. Steroid hormones may be poorly metabolized In patients with
impaired liver function and should be administered with caution In such
patients.
7. Oral contraceptive users may have disturbances In normal tryrp
tophan metabolism which may result in a relative pyrldoxino deficiency.
8. Serum folate levels may be depressed by oral conlracepllve therapy,
Since the pregnant woman is predisposed to the development of tole
deficiency and the Incidence of rlate deficiency Increases with Increso.
Ing gestation, it is possible that if a woman becomes pregnant shortly
after stopping oral contraceptives, she may have a greater chance of
developing folate deficiency and complications attributed to this
deficiency.
9. The patholoCIlt should be advised of oral contraceptive therapy
when relevant specimens are submitted.
10. Certain endocrine and liver function tests and blood components
may be affected by estrogen-containing Oral contraceptives'
a. Increased sulfobromphthalein retention.
b. Increased prothrombin and factors VII, VIII, IX, and X; decreacod
antithrombin 3; increased norepinephrino-inducd platolot aggregabillty,
c. Increased thyroid-binding globulin (TBG) leading to Increascd cir.
culating total thyroid hormone, as measured by protein-bound Iodine
(PBI), T4 by column, or T4 by radioimmunoassay Free T3 resin uptake Is
decreased, reflecting the elevated TBG, tres T4 concentration Is
unaltered.
d. Decreased pregnanedlol excretion.
e. Reduced response to metyrapone test,
INFORMATION FOR THE PATIENT
(See Patient Labeling printed below.)
DRUG INTERACTIONS
Reduced efficacy and increased Incidence of breakthrough bleeding
have been associated with concomitant use of rifampin, A similar
association has been suggested with barbiturates, phonylbutazono,phenytoin sodium, and ampicillin.
CARCINOGENESIS
See WARNINGS section for Information on the carcinogenic potential of
oral contraceptives.
PREGNANCY
Pregnancy category X. See CONTRAINDICATIONS and WARNINGS,
NURSING MOTHERS
See WARNINGS.
ADVERSE REACTIONS
An increased risk of the following serious adverse reactions has boon
associated with the use of oral contraceptives (see WARNINGS):
Thrombophlebitis. Hypertension.
Pulmonary embolism. Gallbladder disease,
Coronary thrombosis. Liver Tumors.
Cerebral thrombosis. Congenital Anomalies
Cerebral hemorrhage.
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PHARMACIST LIABILITY
There i5 .id ence of an association between the following conditions and
the usa of oral contraceptives, although additional confirmatory studies
ar, necded:
Mesenteric thrombosis.
N.-uro-ocular lesions, e.g., retinal thrombosis and optic neuritis.
The following adverse reactions have been reported in patients receiving
oral contraceptives and are believed to be drug-related:
flauea andor vomiting, usually the most common adverse reactions,
occur in approximately 10 percent or less of patients during the first
cycle Other reactions, as a general rule, are seen much less frequently or
only occasionally.
Gastrointestinal symptoms (such as abdominal cramps and bloating).
Breakthrough bleeding.
Spotting.
Change In menstrual flov.
Dysmenorrhea.
Amenorrhea during and after treatment.
Temporary infertility after discontinuance of treatment.
Edema.
Chloasma or melasma which may persist.
Breast changes tenderness, enlargement, and secretion.
Change in weight (increase or decrease).
Change in cervical erosion and cervical secretion.
Possible diminution in lactation when given immediately postpartum.
Cholostatic jaundice.
Migraine.
Increase In size of uterine lelomyomata,
Rash (allergic).
Mental depression.
Roduced tolerance to carbohydrates.
Vaginal candidissls.
Change in corneal curvature (steepening).
Intolerance to contact lenses.
Thu following adverse reactions have been reported in users of oral con-
traceptives, and the association has been neither confirmed nor refuted:
Prcmeonstrual-trke syndrome. Hirsutism.
Cataracts. Loss of scalp hair.
Changes in libido Erythema muttiforme.
Chorea. Eiryhema nodosum.
Changes in appetite. Hemorrhagic eruption.
Cystific.like syndrome. Vaginiltis.
Headache. Porphyria.
Nervousness. Impaired renal function.
Dizziness.
ORTHO-NOVUMI 1iSOC321 snd ORTHO-NOVUM 1150028 contain tar-
trazino. Allergic reactions have been reported with the Ingestion of this
dye In some patients.
ACUTE OVERDOSE
Serious Ill effects have not been reported following acute Ingestion of
large dosos of oral contraceptives by young children. Overdosage may
cause nausea, and withdrawal bleeding may occur In females.
DOSAGE AND ADMINISTRATION
To achleve maximum contraceptive effectiveness, ORTHO-NOVUM
Tablets, MODICON Tablets, and MICRONOR must be taken exactly as
directed and at Intervals not exceeding 24 hours.
21.DAY REGIMEN (21 days on, 7 days of l
The dosage of ORTHO-NOVUM 11500 21, ORTHO-NOVUM 1180021,
ORTHO-NOVUfM 2 mg 0 21 and MODICON for the initial cycle of therapy
ts one tablet administered daily from the 5th day through the 25th day of
the menstrual cycle, counting the first day of menstrual flow as "Day 1."
The use of these products for contraceptton may be Initiated postpartum.
When the tablets are administered during the postpartum period, the In-
creased risk of thromboembolic disease associated with the postpartum
period must be considered. (See CONTR.INDICATIONS. WARNINGS,
and PRECAUTIONS concerning thromboembollc disease.) If ORTHO-
NOVUM 1150 0 21, ORTHO-NOVUM 1180 21. ORTHO-NOVUM 2 mg 0 21
and MODICON Tablets are first taken later than the fifth day of the first
menstrual cycle of medication or postpartum, contraceptive reliance
should not be placed on these products until after the first seven consec.
uilve days of administration For subsequent cycles, no tablets are taken
for 7 days, then a nev course Is started of one tablet a day for 21 days.
The dosage regimen then continues with 7 days of no medication, fol-
locred by 21 days of medication, instituting a three-weeks-on, one-week.
off dosage regimen. The possibility of Ovulation and conception prior to
Initiation of medication should be considered If the patient misses more
than one tablet, the patient should begin taking tablets again as soon as
remembered and another method of contraception used for the balance
of that tablet cycle.
ORTHO-NOVUM 2 mgO2l: Following three months of treatment of
hypermeorrhea, medication may be discontinued to determine the need
for further therapy.
28-DAY REGIMEN (Sunday Start)
Wiron taking ORTHO-NOVUI 1150 0 28, the first yellow tablet should be
taken on the first Sunday after menstruation begins. When taking
ORTHO-NOVUM 11800 28 or MODICON 28, the first white tablet should
be taken on the first Sunday after menstruation begins. If period begins
on Sunday, the first yellow tablet or white tablet is taken on that day.
Tablets are taken without Interruption as follows: One yellow or white
tablet daily for 21 days, then one green tablet daily for 7 days. After 28
tablets have been taken, a yellow or white tablet is then taken the next
day (Sunday) etc. Contraceptive reliance should not be placed on these
products until after the first 7 consecutive days of administration. The
use of ORTHO-NOVUM 1150028, ORTHO-NOVUM 1180028, and
MODICON 28 for contraception may be initiated postpartum. When the
tablets are administered during the postpartum period, the increased risk
of thromboembolic disease associated with the postpartum period must
be considered. (See CONTRAINDICATIONS, WARNINGS, and PRECAU-
TIONS concerning thromboembolic disease.) The possibility of ovulation
and conception prior to initiation of medication should be considered. If
the patient misses more than one tablet, the patient should begin taking
tablets again as soon as remembered and another method of coniracep-
tion used for the balance of that tablet cycle.
MICRONOR (Continuous Regimen)
MICRONOR (norethindrone) is administered on a continuous dally
dosage regim.n starting on the first day of menstruation, i.e., one tablet
each day, every day of the year. Tablets should be taken at the same time
each day and continued daily. The patient should be advised that if pro-
longed bleeding occurs, she should consult her physician.
The use of MICRONOR for contraception may be initiated postpartum
(see WARNINGS section). When MICRONOR is administered during the
postpartum period, the increased risk of thromboembolic disease
associated with the postpartum period must be considered. (See CON-
TRAINDICATIONS. WARNINGS, and PRECAUTIONS concerning throm-
boembolic disease.)
If the patient misses one tablet, MICRONOR should be discontinued im-
mediately and a method of nonhormonal contraception should be used
until mensis has appeared or pregnancy has been excluded.
Alternatively, if the patient has taken the tablets correctly. and if mensis
does not appear when expected, a nonhormonal method of contraception
should be substituted until an appropriate diagnostic procedure is per-
formed to rule out pregnancy.
Other Regimens
In the Initial cycle, the dosage of ORTHO-NOVUM 10 mg for contracep-
tion and hypermenorrhea is one tablet administered daily from the 5th
through the 24th day of the menstrual cycle, counting the first day of
menstrual flow as "Day 1." The use of ORTHO-NOVUM 10 mg for con-
traception may be initiated postpartum. When ORTHO-NOVUM 10 mg is
administered during the postpartum period, the increased risk of throm-
boembolic disease associated with the postpartum period must be con-
sidered. (See CONTRAINDICATIONS, WARNINGS and PRECAUTIONS
concerning thromboembolic disease.) If ORTHO-NOVUM 10 mg is first
taken later than the fifth day of the first menstrual cycle of medication or
postpartum, contraceptive reliance should not be placed on ORTHO-
NOVUM 10 mg until after the first seven consecutive days of administra-
tion. The possibility of ovulation and conception prior to initiation of
medication should be considered. If the patient misses more than one
tablet, the patient should begin taking tablets again as soon as
remembered and another method of contraception used for the balance
of that tablet cycle. In all subsequent cycles the first tablet is taken on
the 7th day following completion of the previous 20-day course, i.e., 6
days without medication. Following three months of treatment of
hypermenorrhea. medication may be discontinued to determine the need
for further therapy.
Clinical experience indicates that the use of ORTHO-NOVUM 10mg in-
definitely postpones menses and controls ovulation, resulting in sympto-
matic and clinical improvement in cases of endometriosis. (a) Suppres-
sive therapy-ORTHO-NOVUM 10 mg daily for 3 to 9 months is sug-
gested with an increase in dose to 20 or 30 mg daily when indicated by
the occurrence of breakthrough bleeding. Duration of treatment is deter-
mined on the basis of clinical findings. (b) Cyclic therapy-Some cases of
endometriosis apparently respond to cyclic therapy with ORTHO-NOVUM
10 mg. which suppresses ovulation. Administer one tablet daily for 20
days (as described above for contraception).
(See discussion of Dose-Related Risk of Thromboembolism from Oral
Contraceptives.)
Breakthrough bleeding, spotting, and amenorrhea are frequent reasons
for patients discontinuing oral contraceptives. In breakthrough bleeding,
as in all cases of irregular bleeding from the vagina, nonfunctional
causes should be borne in mind. In undiagnosed persistent or recurrent
abnormal bleeding from the vagina, adequate diagnostic measures are
indicated to rule out pregnancy or malignancy. If pathology has been ex-
cluded, time or a change to another formulation may solve the problem.
Changing to an oral contraceptive with a higher estrogen content, while
potentially useful in minimizing menstrual irregularity, should be done
only if necessary since this may increase the risk of thromboembolic
disease.
Pregnancy should be ruled out before initiating or continuing the contra-
ceptive regimen. Pregnancy should always be considered if withdrawal
bleeding does not occur.
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HOW SUPPLIED
ORTHO-NOVUM 1150021 Tablets (as yellow unscored tablets with
"Ortho" and "1" debossed on each side) are available in a DIALPAK"
Tablet Dispenser containing 21 tablets and a dispensing unit which con.
tains one DIALPAK and two refills of 21 tablets each. Each yellow
ORTHO-NOVUM 1150021 Tablet contains 1 mg of the progestational
compound. norethindrone, together with 0.05 mg of the estrogenic com-
pound. mestranol.
ORTHO-NOVUM 1150021 is available for clinic usage In a VERIDATE'
Tablet Dispenser (unfilled) and VERIDATE Refills.
ORTHO-NOVUM 1150028 Tablets (as yellow unseated tablets with
"Ortho" and "1" debossed on each side) are available in a DIALPAK
Tablet Dispenser containing 28 tablets, 21 yellow norethindrone with
mestranol tablets and 7 green tablets containing Inert Ingredients. Each
yellow ORTHO-NOVUM 1150028 Tablet contains I mg of the progesta-
lionel compound, norethindrone, together with 0.05 mg of the estrogenic
compound, mestranol.
ORTHO-NOVUM 1150028 is available for clinic usage In a VERIDATE
Tablet Dispenser (unfilled) and VERIDATE Refills.
ORTHO-NOVUM 1180021 Tablets (as white unscored tablets with
"Ortho" and "1" debossed on each side) are available In a DIALPAK
Tablet Dispenser containing 21 tablets and a dispensing unit which con-
tains one DIALPAK and two refills of 21 tablets each. Each white ORTHO-
NOVUM 1180021 Tablet contains I mg of the progestational compound,
norethindrone, together with 0.08mg of the estrogenic compound,
mestranol.
ORTHO-NOVUM 1180021 Is available for clinic usage in a VERIDATE
Tablet Dispenser (unfilled) and VERIDATE Refills.
ORTHO-NOVUM 1180028 Tablets (as white unscored tablets with
"Ortho" and "1" debossed on each side) are available in a DIALPAK
Tablet Dispenser containing 28 tablets, 21 while norethindrone with
mestranol tablets and 7 green tablets containing inert ingredients. Each
white ORTHO-NOVUM 1180028 Tablet contains 1-mg of the progesta-
tional compound, norethindrone, together with 0.08 mg of the estrogenic
compound, mestranol.
ORTHO-NOVUM 1180028 Is available for clinic usage In a VERIDATE
Tablet Dispenser (unfilled) and VERIDATE Refills.
ORTHO-NOVUM 2mg021 Tablets (as white unscored tablets with
"Ortho" and "2' debossed on each side) are available in a DIALPAK
Tablet Dispenser containing 21 tablets. Each white ORTHO-NOVUM
2mg021 Tablet contains 2mg of the progestational compound,
norethindrone, together with 0.10mg of the estrogenic compound.
mestranol.
ORTHO-NOVUM 2mg021 is available for clinic usage in a VERIDATE
Tablet Dispenser (unfilled) and VERIDATE Refills.
ORTHO-NOVUM 10mg Tablets (as white unscored tablets with "Ortho"
and "10" debossed on each side) are available in a DIALPAK Tablet
Dispenser containing 20 tablets. Each white ORTHO-NOVUM 10mg
Tablet contains 10mg of the progestational compound, norethindrone,
together with 0.06 mg of the estrogenic compound. mestranol.
MODICON Tablets (as white unscored tablets with "Ortho" appearing on
each side) are available In a DIALPAK Tablet Dispenser containing 21
tablets. Each white tablet contains 0.5mg of the progestational corn-
pound. norethindrone, together with 0.035mg of the estrogenic com-
pound, ethinyl estradioL
MODICON is available for clinic usage In a VERIDATE Tablet Dispenser(unfilled) and VERIDATE Refills.
MODICON 28 Tablets (as white unseated tablets with "Ortho" appearing
on each side) are available In a DIALPAK Tablet Dispenser containing 28
tablets. 21 white norethindrone with ethinyl estradiol tablets and 7 green
tablets containing inert ingredients. Each white MODICON 28Tablet con-
tains 0.5mg of the progestatlonal compound. norethindrone, together
with 0.035 mg of the estrogenic compound, ethinyl estradiol.
MODICON 28 is available for clinic usage in a VERIDATE Tablet
Dispenser (unfilled) and VERIDATE Refills.
MICRONOR Tablets (as lime unscored tablets with "Ortho" and "035'
debossed on each side) are available in a DIALPAK Tablet Dispenser con-
taiing 35 tablets. Each lime MICRONOR Tablet contains 0.35 mg of the
progestational substance norethindrone.
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The patient labeling for oral contraceptive drug products Is set forth
below:
BRIEF SUMMARY PATIENT PACKAGE INSERT
Cigarette smoking Increases the risk of serious adverse effects
on the heart and blood vessels from oral contraceptive use. This
risk Increases with age and with heavy smoking (15 or more
cigarettes per day) end Is quite marked In women over 35 years
of age. Women who use oral contraceptives should not smoke.
Oral contraceptives taken as directed are about 99 % effective in prevent-ing pregnancy (The mini-pill, however, is somewhat less effective.)
Forgetting to take your pills increases the chance of pregnancy.
Women who have or have had clotting disorders, cancer of the breast or
sex organs, unexplained vaginal bleeding, a stroke, heart attack, angina
pectors., or who suspect they may be pregnant should not use oral con-
traceptives.
Because many risks tncrease with age, birth control pills are not recom-
mended for women past the age of 40
Most side effects of the pill are not serious The most common side ef-
fects are nausea, vomiting, bleeding between menstrual periods, weight
gain, and breast tenderness However, proper use of oral contraceptives
requires that they be taken under your doctor's continuous supervision,
bi cau o thcy can be associated with serious side effects which may be
fatal Fortunately, these occur very infrequently. The serious side effects
I Blood clots in the legs, lungs, brain, heart or other organs and
hemorrhage into the brain due to bursting of a blood vessel.
2 Liver tumors, which may rupture and cause severe bleeding.
3 Birth defects if the pill Is taken white you are pregnant.
4 High blood pressure
5 Gallbladder disease
Some of the symptoms associated with these serious side effects are
discussed In the delailed leaflet given you with your supplyof pils. Notify
your doctor if you notice any unusual physical disturbance while taking
the pill
Thy estrogen in oral contraceptives has been found to cause breast
cancer and other cancers in certain animals. These findings suggest that
oral contraceptives may also cause cancer in humans. However, studies
to date in women taking currently marketed oral contraceptives have not
confirmed that oral contraceptives cause cancer in humans.
The detailed leaflet describes more completely the benefits and risks of
oral contraceptives It also provides Informalion on other forms of con-
traception Read it carefully If you have any questions, consult your
doctor
Caution Oral contraceptives are of no value in the prevention or treat-
ment of venereal disease
DETAILED PATIENT LABELING
WHAT YOU SHOULD KNOW ABOUT ORAL CONTRACEPTIVES
Oral eonlrac eies 'the pill i are the most effective way (except for
-leriZilonl to pre.ent pregnancy They are also convenient and. for most
irrnc free of serious or unpleasant side effects Oral contraceptives
mnvt I.oa.vays be takeni und-r the continuous supervision of a physician
Tt r information in this leaflet under the headings "Who Should Not Use
Oral Contracvplieos The Dangers of Oral Contracepives' and"Howto
U- Oral Contraceptives As Effectively As Possible. Once You Have
Dcvd to Use Tem' is also applicable when these drugs are used for
othe i vdicatlion
ORTHO IIOVUM 2mg may be prescribed for you for the treatment of
hypermi,norhea
ORTHO-NOVUM 10mg may be prescribed for you for the treatment of
hipeirmenorrhea and endometriosis
It is important that any woman who considers using an oral contraceptive
understand the risks involved. Although the oral contraceptives have im-
portant advantages over other methods of contraception, they have cer-
tain risks that no other method has Only you can decide whether the ad-
vantages are worth these risks This leaflet will tell you about the most im-
portant risks. It will explain how you can help your doctor prescribe the pill
as safely as possible by telling him about yourself and being alert for the
earliest signs of trouble. And it wil tell you how to use the pill properly, so
that it witl be as effective as possible There is more detailed information
available in the leaflet prepared for doctors Your pharmacist can show
you a copy; you may need your doctor's help in understanding parts of it.
WHO SHOULD NOT USE ORAL CONTRACEPTIVES
A. Ift you have now, or have had in the past, any of the following condi-
tions you should not use the pill
1 Heart attack or stroke.
2 Clots in the legs or lungs.
3 Angina pectoris
4 Known or suspected cancer of the breast or sex organs.
5. Unusual vaginal bleeding that has not yet been diagnosed.
B If you are pregnant or suspect that you are pregnant, do not use the
pill.
C. Cigarette smokting Increases thes rik of serious adverse
effects on the heart and blood vessels from oral contracep-
lIve use. ThIs rfskIncrasse with age and with heay smoking
(15 or more clgarettee perday) and Is quite marked In women
over 35 yearn of ag. Women who use oral contraceptives
should not smoke.
D. If you have scanty or Irregular periods or are a young woman without a
regular cycle, you should use another method of contraception
because, If you use the pill, you may have difficulty becoming preg-
nant or may fall to have menstrual periods after discontinuing the pill.
B_ Although It is your decision, since many risks increase with age, birth
control pills are not recommended for women past the age of 40.
DECIDING TO USE ORAL CONTRACEPTIVES
If you do not have any of the conditions listed above and are thinking
about using oral contraceptives, to help you decide, you need information
about the advantages and risks of oral contraceptives and of other con-
traceptIve methods as well. This leaflet describes the advantages and
risks of oral contraceptives. Except for sterilization, the IUD and abortion,
which have their own exclusive risks, the only risks of other methods of
contraception are those due to pregnancy should the method fail. Your
doctor can answer questions you may have with respect to other methods
of contraception. He can also answer any questions you may have after
reading this leaflet on oral contraceptives.
1. What Oral Contraceptives Are and How They Work. Oral Contracep-
tives are of two types. The most common, often simply called "the pill," is
a combination of an estrogen and a progestogen, the two kinds of female
hormones. The amount of estrogen and progestogen can vary, but the
amount of estrogen is most important because both the effectiveness and
some of the dangers of oral contraceptives are related to the amount of
estrogen. This kind of oral contraceptive works principally by preventing
release of an egg from the ovary. When the amount of estrogen is 50
micrograms or more, and the pill is taken as directed, oral contraceptives
are more than 99% effective (i.e., there would be less than one pregnancy
if 100 women used the pIlt for one year). Pills that contain 20 to 35 micro.
g rams of estrogen vary slightly in effectiveness, ranging from 98% to more
than 99% effective.
The second type of oral contraceptive, often called the "mini-pill," con-
tains only a progestogen. It works In part by preventing release of an egg
from the ovary but also by keeping sperm from reaching the egg and by
making the uterus (womb) less receptive to any fertilized egg that reaches
it. The mini-pill is less effective than the combination oral contraceptive,
about 97% effective. In addition, the progestogen-only pill has a tendency
to cause irregular bleeding which may be quite inconvenient, or cessation
of bleeding entirely. The progestogen-only pill is used despite its lower ef-
fectiveness in the hope that it will prove not to have some of the serious
side effects of the estrogen-containing pill (see below) but it is not yet cer-
tain that the mini-pill does in fact have fewer serious side effects. The
discussion below, while based mainly on information about the combina-
tion pills, should be cons)dered to apply as well to the mini-pill.
2. Other Nonsurglcal Ways to Prevent Pregnancy. As this leaflet will ex-
plain, oral contraceptives have several serious risks. Other methods of
contraception have lesser risks or none at all. They are also less effective
than oral contraceptives, but, used properly, may be effective enough for
many women. The following table gives reported pregnancy rates (the
number of women out of 100 who would become pregnant in one year) for
these methods:
Pregnancies Per 100 Women Per Year
Intrauterine device (IUD), less than 1-6;
Diaphragm with spermicidal products (creams or jellies), 2-20;
Condom (rubber), 3-36; Aerosol foams, 2-29; Jellies and creams, 4-36;
Periodic abstinence (rhythm) all types, less than 1.47;
1. Calendar method, 14-47;
2. Temperature method, 1-20;
3. Temperature method-Intercourse only in postovulatory phase,
less than 1.7;
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4. MucuS method, 1-25;
No contraception, 60-80.
The figures (except for the IUD) vary widely because people differ In how
-well they use each method. Very faithful users of the various methods
obtain very good results, except for users of the calendar method of
periodic abstinence (rhythm). Except for the IUD, effective use of these
methods requires somewhat more effort than simply taking a single pill
every moming, but It Is an effort that many couples undertake success-
fully. Your doctor can tell you a great deal more about these methods of
contraception.
3. The Dangers of Oral Contraceptives.
a. Circulatory disorders (abnormal blood clotting, heart aftack, and
stroke due to hemorrhage). Blood clots (in various blood vessels of the
body) are the most common of the serious side effects of oral contracep-
tives. A clot can result in a stroke (if the clot is In the brain), a heart attack
(if the clot is In a blood vessel of the heart), ora pulmonary embolus (a clot
which forms In the legs or pelvis, then breaks off and travels to the lungs).
Any of these can be fatal. Clots also occur rarely in the blood vessels of
the eye, resulting In blindness or impairment of vision in that eye. There Is
evidence that the risk of clotting increases with higher estrogen doses. It
Is therefore important to keep the dose of estrogen as low as possible, so
long as the oral contraceptive used has an acceptable pregnancy rate and
doesn't cause unacceptable changes In the menstmal pattern. Further.
more, cigarette smoking by oral contraceptive users increases the risk of
serious adverse effects on the heart and blood vessels. This risk increases
with age and with heavy smoking (15 or more cigarettes per day) and
begins to become quite marked In women over 35 years of age. For thisjroason, women who use oral contraceptives should not smoke.
The risk of abnormal blood clotting Increases with age In both users and
nonusers of oral contraceptives, but the Increased risk from the oral con-
traceptive appears to be present at all ages. For women aged 20 to 44 It Is
estimated that about 1 In 2,000 using oral contraceptives will be
hospitalized each year because of abnormal clotting. Among nonusers In
the same age group, about 1 In 20,000 would be hospitalized each year.
For oral contraceptive users In general, it has been estimated that In
women between the ages of 15 and 34 the risk of death due to a circulatory
disorder is about 1 in 12,000 per year, whereas for nonusers the rate Is
about 1 In 50,000 peryear. In the agegroup35 to44, the risk isestimated to
be about I In 2,500 per year for oral contraceptive users and about 1 In
10,000 per year for nonusers.
Even without the pill the risk of having a heart attack increases with age
and is also increased by such heart attack risk factors as high blood
pressure, high cholesterol, obesity, diabetes, and cigarette smoking.
Without any risk factors present, the use of oral contraceptives alone may
double the risk of heart attack. However, the combination of cigarette
smoking, especially heavy smoking, and oral contraceptive use greatly In-
creases the risk of heart attack. Oral contraceptive users who smoke are
about five times more likely to have a heart attack than users who do not
smoke and about ten times more likely to have a heart attack than
nonusers who do not smoke. It has been estimated that users between the
ages of 30 and 39 who smoke have about a 1-1n10,000 chance each yearof
having a fatal heart attack compared to about a 1.1in-50,000 chance In
users who do not smoke, and about a 1-in100,000 chance In nonusers
who do not smoke. In the age group 40 to 44, the risk is about 1 In 1,700 per
year for users who smoke compared to about 1 In 10,000 for users who do
not smoke and to about one In 14,000 per year for nonusers who do not
smoke. Heavy smoking (about 15 cigarettes or more a day) further in-
creases the risk. If you do not smoke and have none of the other heart at-
tack risk factors described above, you will have a smaller risk than listed. If
you have several heart attack risk factors, the risk may be considerably
greater than listed.
In addition to blood-clotting disorders, it has been estimated that women
taking oral contraceptives are twice as likely as nonusers to have a stroke
due to rupture of a blood vessel In the brain.
One report suggests that the risk of circulatory diseases appears to
Increase the longer you are on the pill and may continue after you stop.
b. Formaton of tumors Studies have found that when certain animals
are given the female sex hormone estrogen, which Is an Ingredient of oral
contraceptives, continuously for long periods, cancers maydevelop In the
breast, cervix, vagina, and liver.
These findings suggest that oral contraceptives may cause cancer In
humans. However, studies to date in women taking currently marketed
oral contraceptives have not confirmed that oral contraceptives cause
cancer In humans. Several studies have found no Increase In breast
cancer In users, although one study suggested oral contraceptives might
cause an increase in breast cancer in women who already have benign
breast disease (e.g., cysts).
Women with a strong family history of breast cancer or who have breast
nodules, fibrocystic disease, or abnormal mammograms or who were ex.
posed to DES (diethylstilbestrol), an estrogen, during their mother's
pregnancy must be followed very closely by their doctors if they choose to
useoral contraceptives instead ofanothermethod of conlraceptlon. Many
studies have shown that women taking oral contraceptives have less risk
of getting benign breast disease than those who have not used oral con-
traceptives. Recently, strong evidence has emerged that estrogens (one
component of oral contraceptives), when given for periods of more than
one year to women after the menopause, Increase the risk of cancer of the
uterus (womb). There Is also some evidence that a kind of oral contracep-
live which is no longer marketed, the sequential oral contraceptive, may
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Increase the risk of cancer of the uterus. There remains no evidence,
however, that the oral contraceptives nowv available Increase the risk of
this cancer.
Oral contraceptives do cause, although rarely, a benign (non-malignant)
tumor of the liver. These tumors do not spread, but they may rupture and
cause Internal bleeding, which may be fatal. A few cases of cancer of the
liver have been reported in women using oral contraceptives, but It Is not
yet known whether the drug caused them.
c. Dangers to a developing child I oral contraceptives are usedin orIm.
mediately preceding pregnancy. Oral conlraceptives should not be taken
by pregnant women because they may damage the developing child, An
Increased risk of birth defects. Including heart defects and limb defects,
has been associated with the use of Sex hormones, Including oral con
traceptives, In pregnancy. In addition, the developing female child whose
mother has received DES (diothylstilbotlroI), an estrogen, during preg.
nancy has a risk of getting cancer of the vagina or cervix In hor tencs or
young adulthood. This risk Is estimated to be about 1 to 4 In 1000 ex.
posures. Abnormalities of the urinary and sex organs have been reported
In male offspring so exposed. Il Is possible that other estrogens, such as
the estrogens In oral contraceptives, could have the same elfect In the
child If the mother takes them during pregnancy.
If you stop taking oral contraceptives to become pregnant, your doctor
may recommend that you use another method of contraceptIon fota short
while, for example three months. The reason for this ia that there In
evidence from studies In women who have had *miscarriages" soon ofter
stopping the pill, that the lost fetuses are more likely to be abnormal.
Whether there Is an overall Increase In "miscarriage" In women who
become pregnant soon after stopping the pill as compared with women
who do not use the pill 13 not known, but It Is possible that there may be, If,
however, you do become pregnant soon after stopping oral contracep-
tives, and do not have a miscarriage, there does not appear to be evidence
that the baby has an Increased risk of being abnormal,
d. Gallbladder disease. Women who use oral contraceplives have a
greater risk than nonusers of having gallbladder disease requiring
surgery. The Increased risk may first appear within one year of use end
may double after four or five years of use.
e. Other side effects of oral contraceptives. Some women using oral
contraceptives experience unpleasant side effects. Some of those may be
temporary. Your breasts may feel tender, nausea and vomiting may occur,
you may gain or lose weight, and your ankles may swell A spotty darken
Ing of the skin, particularly of the face, Is possible and may persist. You
may notice unexpected vaginal bleeding or changes In your menstrual
period. Irregular bleeding Is frequently seen when using the mIni-pill or
combination oral contraceptives containing less than 50 micrograms of
estrogen.
More serious side effects Include worsening of migraine, asthma,
epilepsy, and kidney or heart disease becauseo f a tendency for water to
be retained In the body when oral contraceptives are used. Other side of.
facts are growth -f preexisting fibrold tumors of the uterus; mental
depression; and liver problems with jaundice (yellowing of the skin). Your
doctormay find that levels of sugarand fatty substences In yourblod are
elevated; the long-term effects of these changes are not known, Some
women develop high blood pressure while taking oral conlraceptIveo,
which ordinarily returns to the original levels when the oral conlrecoptlvo
Is stopped.
Other reactions. although not proved to be caused by oral contraceptives,
are occasionally reported. These Include mere frequent urination end
some discomfort when urinating, kidney disease, nervousness, dizziness,
some loss of scalp hair, an Increase In body hair, an increase or decrease
In sex drive, appetite changes, cataracts, and a need for a change In con
tact lens prescription or Inability to use contact tenses.
After you stop using oral contraceptives there may be a delay before you
are able to become pregnant or before you resume having menstrual
periods. This Is especially trus of women who had Irregular menstrual
cycles prior to the use of oral contraceptives. As dlccursLd previously,
yourdoctor may recommend that you wait a short while after stopping the
pill before you try to become pregnant. During this lime, use another form
of coentraception. You should consult your physician before resuming usa
of oral contraceptives after childbirth, espolally If you plan to nurse your
baby. Drugs Inoral contraceptives are known toappoar In thu milk, and the
long-range effect on Infants Is not known at this time Furthermore, oral
contraceptives may cause a decrease In yourmIlk supply as well as In the
quality of the milk.
4. Comparison of the Risks of Oral Contraceptives and Other Contracp
tIre Methods.The many studies on the risks and offeotlvonoss of oral con-
traceptlves and other methods of contraception have been analyzed to
estimate the risk of deth associated with various methods of conlrac p
tlIon. This risk has two parts: (a) the risk of the method Itself (e.g., the risk
that oral contraceptives will cause death duo to abnormal clotting), and
(b) the risk of death due to pregnancy or abortion In the event the method
falls. The results of this analysis era shown In the bargraph(Figure 1). The
height of the bars Is the number of deaths per 100,000 woman each year.
There are six sets of bars, each set referring to a zpocillo ego group of
women. Within each set of bars there Is a single bar for each of the dif.
ferent contraceptive methods. For oral contraceptives, there are two
bars-one for smokers and the other for nonsmokers. The analysis Is
based on present knowledge and now Informalton could, of course, olter
It. The analysis shows that the risk of death from all methods of birth con.
trot s low and below that associated with childbirth, except for oral con.
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traceptives In women over 40 who smoke. It shows that the lowest risk of
death Is associated with the condom or diaphragm (traditional contracep-
tion) backed up by early abortion In case of failure of the condom or
diaphragm to prevent pregnancy. Also, at any age the risk of death (due to
unexpected pregnancy) from the use of traditional contraception, even
without a backup of abortion, Is generally the same as or less than that
from use of oral contraceptives.
HOW TO USE ORAL CONTRACEPTIVES AS EFFECTIVELY
AS POSSIBLE, ONCE YOU HAVE DECIDED TO USE THEM
1. What to Tell your Doctor.
You can make use of the pill as effectively as possible by telling your doc-
for if you have any of the following:
a. Conditions that mean you should not use oral contraceptives:
Clots In the legs or lungs.
Clots In the legs or lungs In the past.
A stroke, heart attack, or angina pectoris.
Known or suspected cancer of the breast or sex organs.
Unusual vaginal bleeding that has not yet been diagnosed.
Known or suspected pregnancy.
b. Conditions that your doctor will want to watch closely or which
might cause him to suggest another method of contraception:
A family history of breast cancer.
Breast nodules, fibrocystlc disease of the breast, or an abnormal
mammogram. Heart or kidney disease.
Diabetes. Epilepsy.
High blood pressure. Mental depression.
High cholesterol. Fibrold tumors of the uterus.
Cigarette smoking. Gallbladder disease.
Migraine headaches.
c. Once you are using oral contraceptives, you should be alert for
signs of a serious adverse effect and call your doctor If they occur.
Sharp pain In the chest, coughing blood, or sudden shortness of
breath (indicating possible clots In the lungs).
Pain In the calf (possible clot In the leg).
Crushing chest pain or heaviness (indicating possible heart attack).
Sudden severe headache or vomiting, dizziness or fainting, disturb-
ance of vision or speech orweakness or numbness In an arm or leg (in-
dicating a possible stroke).
Sudden partial or complete loss of vision (indicating a possible clot in
the erye).
Breast lumps (you should ask your doctor to show you how to ex-
amine your own breasts).
Severe pain In the abdomen (indicating a possible ruptured tumor of
the lver).
Severe depression.
Yellowing of the skin Uaundice).
2. How to Take the Pill So That It Is Most Effective.
To achieve maximum contraceptive effectiveness, ORTHO-NOVUM
MODICOIN and MICRONOR must be taken exactly as directed and at Inter-
vals not exceeding 24 hours.
21.Day Regimen: Counting the first day of menstrual flow as "Day 1,.
take one tablet daily from the Sth through the 25th day of the
menstrual cycle. If the first tablet Is taken later than the 5th day of the
menstrual cycle or postpartum, contraceptive reliance should not be
placed on ORTHO-NOVUM or MODICON until after the first seven
consecutive days of administration. Take a tablet the same time each
day, preferably at bedtime, for 21 days, then wait for 7 days during
which time a menstrual period usually occurs. Following this 7-day.
waiting period, start taking a tablet each day for the next 21 days, thus
using a three-weeks-on, one-week-off dosage regimen.
28-Day Regimen: The first white or yellow tablet should be taken on
the first Sunday after the menstrual period begins. If period begins on
Sunday. begin taking tablets that day. Take one while oryellow tablet
at the same time each day for 21 consecutive days, then take one
green tablet dally for 7 days during which time your menstrual period
usually occurs. During the FIRST cycle, it Is Important that you use
another method of birth control until you have taken a white or yellow
tablet daily for seven consecutive days. After 28 tablets have been
taken. (last green tablet will always be taken on a Saturday) take the
first tablet (white or yellow) from your next package the following day(Sunday) whether or not you are still menstruating. With the 28-day
regimen, pills are taken every day of the year.
20-Day Regimen: In the initial cycle, the dosage of ORTHO-NOVUM
10 mg for contraception Is one tablet administered daily from the 5th
through the 24th day of the menstrual cycle, counting the first day of
the menstrual flow as "Day 1'. If ORTHO-NOVUM 10 mg is first taken
later than the fifth day of the first menstrual cycle of medication or
postpartum, contraceptive reliance should not be placed on ORTHO-
NOVUM 10mg until after the first seven consecutive days of ad-
ministration. In all subsequent cycles the first tablet Is taken on the
7th day following completion of the previous 20-day course, Le., 6
days without medication.
In the treatment of hypermenorrhea and endometriosis, your physi-
clan will discuss the regimen with you.
Continuous Regimen (MICRONOR): The first MICRONOR Tablet
should be taken on the first day of the menstrual period.
Take one tablet at the same time each day without interruption for as
long as contraceptive protection is desired.
The effectiveness of progestogen-only oral contraceptives, such as
MICRONOR, is lowerthan that of the combination oral contraceptives
containing both estrogen and progestogen. If 100 women utilized an
estrogen-containing oral contraceptive fora period of oneyear, gener-
ally less than one pregnancy would be expected to occur however, If
MICRONOR had been utilized, approximately three pregnancies
might occur.
Women who participated in the clinical studies with MICRONOR and
who had not taken other oral contraceptives before starting
MICRONOR had a higherpregnancy rate(fourwomen out of 100), par-
ticularly during the first six months of therapy, and to a large extent
because they did not take their tablets correctly.
Of course, if you don't take your tablets as directed, or fqrget to take
them every day, the chance you may become pregnant Is naturally
greater.
MICRONOR (norethindrone) will probably cause some changes In
your menstrual pattern. Your cycle, that is the time between
menstrual periods, will vary. For example, you might have a 28-day
cycle, followed by a 17-day cycle, followed by a 35-day cycle, etc. This
Is common with MICRONOR.
While using MICRONOR, your period may be longer or shorter than
before. If bleeding lasts more than eight days, be sure to let your doc-
tor know.
Occasionally women who are not taking the pill miss a period. This Is also
true for women taking the pill and it has been reported to occur as fre-
quently as several times each year In some women, depending on various
factors, such as age and prior history. Therefore, If you miss a period, or if
you are taking mini-pills and It is45 days or more from the start of your last
menstrual period you may be pregnant and you should consult your physi-
cian before continuing to take the pil. (Yourdoctor Is the best sourceof In-
formation about this.) The pill should not be used when you are pregnant
because of some reports of the possibility of adverse effects on the
developing child. Very rarely, women who are using the pill as directed
become pregnant. The likelihood of becoming pregnant if you occasion-
ally miss one or two pills is naturally higher. If you miss a period, espe-
cially if you have not taken the pill regularly, you should use an atermative
method of contraception until pregnancy has been ruled out. If you have
missed more than one tablet at any time, you should immediately start
using an additional method of contraception and complete yourpill cycle.
3. Periodic Examlnatlon
Your doctor will take a complete medical and family history before
prescribing oral contraceptives. At that time and about once a year
thereafter, he will generally examine your blood pressure, breasts.
abdomen, and pelvic organs (including a Papanicolaou smear, I.e., test for
cancer).
Summary
Oral contraceptives are the most effective method, except sterilization, for
preventing pregnancy. Other methods, when used conscientiously, are
also very effective and have fewer risks.
Women who use oral contraceptives should not smoke.
In addition, if you have certain conditions or have had these conditions in
the past, you should not use oral contraceptives because the risk is too
great. These conditions are listed in the booklet. If you do not have these
conditions and decide to use the "pill.' please read the booklet carefully
so that you can use the "pill."
Based on his or her assessment of your medical needs, your doctor has
prescribed this drug for you. Do not give the drug to anyone else.
ORTHO PHARMACEUTICAL CORPORATION
Raritan, New Jersey 08869
ORTHO PHARMACEUTICALS. INC.
Dorado. Puerto RiCO 00646
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